
# **Cell Reports**

# Family-wide Structural and Biophysical Analysis of Binding Interactions among Non-clustered $\delta\text{-Protocadherins}$

## **Graphical Abstract**



# Authors

Oliver J. Harrison, Julia Brasch, Phinikoula S. Katsamba, ..., Bridget Carragher, Barry Honig, Lawrence Shapiro

## Correspondence

bh6@columbia.edu (B.H.), lss8@columbia.edu (L.S.)

# In Brief

Non-clustered  $\delta$ -protocadherins are adhesion molecules linked to a number of neurological disorders. Harrison et al. apply biophysical and structural methods across the family to show preferential self-binding through a canonical interface and disordered assemblies of adhesive dimers between membranes that diverge from ordered assemblies of close relatives clustered protocadherins.

## **Highlights**

- δ-pcdh adhesive interactions are preferentially homophilic with distinct affinities
- δ1- and δ2-pcdhs form canonical adhesive dimers with divergent specificity regions
- Ectodomain-mediated *cis* interactions are not observed, in contrast to clustered pcdhs
- Assemblies at contact sites differ markedly from those of clustered pcdhs





# Family-wide Structural and Biophysical Analysis of Binding Interactions among Non-clustered $\delta$ -Protocadherins

Oliver J. Harrison,<sup>1,2,6</sup> Julia Brasch,<sup>1,2,5,6</sup> Phinikoula S. Katsamba,<sup>1,2</sup> Goran Ahlsen,<sup>1,2</sup> Alex J. Noble,<sup>5</sup> Hanbin Dan,<sup>3</sup> Rosemary V. Sampogna,<sup>3</sup> Clinton S. Potter,<sup>1,5</sup> Bridget Carragher,<sup>1,5</sup> Barry Honig,<sup>1,2,3,4,\*</sup> and Lawrence Shapiro<sup>1,2,7,\*</sup> <sup>1</sup>Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA

<sup>2</sup>Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA

<sup>3</sup>Department of Medicine, Division of Nephrology, Columbia University, New York, NY 10032, USA

<sup>4</sup>Department of Systems Biology, Columbia University, New York, NY 10032, USA

<sup>5</sup>National Resource for Automated Molecular Microscopy, Simons Electron Microscopy Center, New York Structural Biology Center, New York, NY 10027, USA

<sup>6</sup>These authors contributed equally

7Lead Contact

\*Correspondence: bh6@columbia.edu (B.H.), lss8@columbia.edu (L.S.) https://doi.org/10.1016/j.celrep.2020.02.003

#### SUMMARY

Non-clustered  $\delta 1$ - and  $\delta 2$ -protocadherins, close relatives of clustered protocadherins, function in cell adhesion and motility and play essential roles in neural patterning. To understand the molecular interactions underlying these functions, we used solution biophysics to characterize binding of  $\delta$ 1- and  $\delta$ 2-protocadherins, determined crystal structures of ectodomain complexes from each family, and assessed ectodomain assembly in reconstituted intermembrane junctions by cryoelectron tomography (cryo-ET). Homophilic trans (cell-cell) interactions were preferred for all  $\delta$ -protocadherins, with additional weaker heterophilic interactions observed exclusively within each subfamily. As expected,  $\delta$ 1- and  $\delta$ 2-protocadherin *trans* dimers formed through antiparallel EC1-EC4 interfaces, like clustered protocadherins. However, no ectodomain-mediated cis (same-cell) interactions were detectable in solution; consistent with this, cryo-ET of reconstituted junctions revealed dense assemblies lacking the characteristic order observed for clustered protocadherins. Our results define non-clustered protocadherin binding properties and their structural basis, providing a foundation for interpreting their functional roles in neural patterning.

#### **INTRODUCTION**

Members of the cadherin superfamily function in a wide variety of calcium-dependent cell adhesion and recognition processes and are characterized by consecutive extracellular cadherin (EC) repeats. Classical type I, type II, and desmosomal cadherins contain four to five EC repeats and form adhesive *trans* interac-

tions between cells via N-terminal EC1 domains (Brasch et al., 2012). Outside of these well-characterized proteins, cadherin superfamily members containing more than five EC repeats have been loosely termed protocadherins (pcdhs). The largest groups within the protocadherin branch are the clustered protocadherins (pcdh $\alpha$ , pcdh $\beta$ , and pcdh $\gamma$ ), encoded by a contiguous gene cluster subject to alternative splicing (Mountoufaris et al., 2018; Rubinstein et al., 2017), and the non-clustered  $\delta$ -protocadherins - subjects of the current study-whose genes are dispersed in the genome (Kim et al., 2007; Light and Jontes, 2017; Morishita and Yagi, 2007; Redies et al., 2005). Both families encode singlepass transmembrane proteins containing six or seven EC domains and are closely related in their extracellular regions (~30%-40% identity). Clustered protocadherins function primarily in neurite self-avoidance (Lefebvre et al., 2012; Mountoufaris et al., 2017) and branching (Molumby et al., 2016), distinct from the primarily adhesive roles of classical and desmosomal cadherins (Brasch et al., 2018; Harrison et al., 2016; Meng and Takeichi, 2009), while functional roles of non-clustered  $\delta$ -protocadherins remain to be fully characterized.

The non-clustered  $\delta$ -protocadherins comprise nine typical members in human and mouse, divided into  $\delta$ 1- and  $\delta$ 2-subfamilies with four and five members, respectively (Hulpiau and van Roy, 2009). 81-protocadherins contain seven EC repeats and are characterized by conserved CM1, CM2, and CM3 sequence motifs of unknown structure and function in their cytoplasmic domains (Redies et al., 2005; Vanhalst et al., 2005). S2-protocadherins have six EC repeats and contain only CM1 and CM2 (Hulpiau and van Roy, 2009). In addition to the nine canonical family members, the related proteins pcdh12 and pcdh20 represent atypical δ-protocadherins that diverge primarily in their intracellular regions (Hulpiau and van Roy, 2009). Each δ-protocadherin is expressed in a spatiotemporally regulated pattern in the nervous system and other tissues (Blevins et al., 2011; Cooper et al., 2016; Etzrodt et al., 2009; Gaitan and Bouchard, 2006; Kim et al., 2011; Lin et al., 2012). Overlapping expression in vivo suggests that functional specificity could be derived from expression of multiple  $\delta$ -protocadherins in the same cell (Bisogni et al., 2018; Kim et al., 2007). *In vitro* studies have demonstrated that most  $\delta$ -protocadherins mediate homophilic cell aggregation (Bisogni et al., 2018; Pederick et al., 2018), consistent with functions involving cell adhesion and recognition. In addition, a number of  $\delta$ -protocadherins are associated with neurological diseases (Kahr et al., 2013; Kim et al., 2011).

Likely the best understood of the  $\delta$ -protocadherins is the  $\delta$ 2-family member pcdh19. Mutations in the *Pcdh19* gene underlie X-linked *Pcdh19*-girls clustering epilepsy (*Pcdh19*-GCE), which manifests in heterozygous females, but not in hemizygous males. Pederick et al. (2018) showed that mosaic expression of wild-type and inactive pcdh19 in heterozygous mutant female mice led to abnormal sorting in which neural progenitors expressing wild-type pcdh19 separated from those expressing the mutant, demonstrating that pcdh19 homophilic adhesion can effect cell localization. Functional roles dependent on homophilic recognition have also been suggested for pcdh17 in collective axon extension (Hayashi et al., 2014) and pcdh7 in axon guidance (Leung et al., 2013).

Crystal structures of pcdh19 from zebrafish (Cooper et al., 2016) and a crystal structure of human pcdh1 published while this paper was under review (Modak and Sotomayor, 2019) revealed the trans binding mechanism for  $\delta 1$ - and  $\delta 2$ -protocadherins to be consistent with that observed for the related  $\alpha$ -,  $\beta$ -, and  $\gamma$ -clustered protocadherins (Goodman et al., 2016a, 2016b). In each trans-dimer structure, EC1-EC4 regions of partner molecules bind in an antiparallel orientation to form a dimer mediated by two EC1:EC4 and two EC2:EC3 interfaces related by 2-fold symmetry. Clustered protocadherins have been shown to additionally form asymmetrical EC5-EC6:EC6 cis dimers (Goodman et al., 2017) that are proposed to function in combination with trans interactions to allow combinatorially expressed isoforms to impart distinct cellular identities to individual neurons (Brasch et al., 2019; Rubinstein et al., 2015). It has not been clear whether δ-protocadherins participate in similar *cis* interactions.

Here we use solution biophysics to analyze homophilic and heterophilic binding of human  $\delta 1$ - and  $\delta 2$ -protocadherins, showing *trans* dimerization to be preferentially homophilic, with weaker heterophilic interactions within subfamilies; and present crystal structures of *trans*-binding fragments from four  $\delta 2$ - and one  $\delta 1$ -protocadherin to identify regions likely to govern *trans*-interaction specificity. We also show that, distinct from clustered protocadherins,  $\delta$ -protocadherins form no detectable ectodomain–*cis* interactions in solution, lack conservation of *cis*-interface regions, and concentrate between membranes as *trans* dimers without higher-order zipper-like structures characteristic for clustered-protocadherin.

#### RESULTS

#### δ-Protocadherin *trans* Interactions Are Preferentially Homophilic

We characterized *trans* binding specificity across the human  $\delta$ -protocadherin family using surface plasmon resonance (SPR). Ectodomain fragments composed of adhesive domains EC1–EC4 were prepared for  $\delta$ 1-pcdh-1, -7, -9, and -11, and for  $\delta$ 2-pcdh-10, -17, -18, and -19, comprising all typical members of each branch (Figure 1A) except for pcdh8, which was

not analyzed in SPR due to poor solubility. We attempted to produce atypical members pcdh12 and -20, which are phylogenetically related to  $\delta$ 2- and  $\delta$ 1-protocadherins, respectively (Figure 1A). Pcdh20 could not be expressed, but pcdh12 was produced as a full ectodomain fragment (EC1–EC6). To test all potential interactions, separate surfaces were prepared from biotinylated forms of each protocadherin binding fragment and analytes were tested over each (Figure 1B).

Specific binding was detected over all protocadherin surfaces (rows) with each displaying a distinct binding profile (Figure 1B). Over a pcdh1 surface, the highest binding response was for homophilic interactions with soluble pcdh1 (Figure 1B, top row). A weaker heterophilic binding response was also detected to pcdh11, another member of the  $\delta$ 1-subfamily, while other analytes, including all  $\delta$ 2-protocadherins, showed no binding to pcdh1 above background (Figure 1B, top row). Heterophilic binding of pcdh1 with two other members of the  $\delta$ 1-subfamily, pcdh7 and -9, was additionally detectable at low levels when pcdh1 was present in the analyte phase (Figure 1B, left column).


Pcdh-7, -9, -11, -10, -12, -17, -18, and -19 displayed analogous binding profiles within which their respective homophilic interactions gave the highest binding responses (Figure 1B, diagonal). Weaker heterophilic binding was also observed for a subset of interactions (Figure 1B). This was restricted within subfamilies and no binding between  $\delta$ 1- and  $\delta$ 2-protocadherins was observed in any combination, suggesting them to be incompatible (Figure 1B). Within the  $\delta$ 1-family, heterophilic interactions were extensive and were observed for all subtype combinations except for that of pcdh9 with pcdh11 (Figure 1B). Heterophilic binding within the  $\delta$ 2-family was observed only for a limited subset and response levels were markedly low compared to the respective homophilic interactions (Figure 1B). Binding of pcdh12 to pcdh17 and -18 was detected in both orientations of analyte and surface, while other **\delta2-heterophilic** combinations showed poor correspondence between the two orientations, likely reflecting weak binding close to the limits of detection (Figure 1B). Uniquely, pcdh19 displayed exclusively homophilic binding with no heterophilic responses detected above background (Figure 1B).


We also tested binding of pcdh1, -7, -10, and -18 EC1–EC4 fragments to surfaces of representative clustered protocadherins  $\alpha$ 7 EC1–EC5,  $\beta$ 6 EC1–EC4,  $\gamma$ A8 EC1–EC4,  $\gamma$ B2 EC1–EC5, and  $\gamma$ C4 EC1–EC4 (Figure S1). No binding of the  $\delta$ -protocadherins over these surfaces was detected, while homophilic binding showed strong responses, suggesting that these families do not *trans*-interact.

# $\delta\text{-Protocadherins}$ Have Differential Homophilic Affinities in the Low Micromolar Range

We determined homophilic binding affinities for all  $\delta$ -protocadherins using sedimentation equilibrium analytical ultracentrifugation (AUC), since determination of K<sub>D</sub> values from SPR data is unreliable for proteins that self-associate (Rich and Myszka, 2007). Full ectodomain fragments encompassing domains EC1–EC7 ( $\delta$ 1) or EC1–EC6 ( $\delta$ 2) were prepared for AUC analysis. Most proteins yielded apparent molecular weights in AUC intermediate between monomer values determined from mass spectrometry and dimer values, suggesting monomer–dimer

Α





#### Figure 1. SPR Analysis of trans Binding Interactions in the $\delta\mbox{-}Protocadherin Family$

(A) Phylogenetic tree of human δ-protocadherins from aligned full-length amino acid sequences. Atypical members italicized. Scale indicates protein distance.
 (B) SPR binding profiles of δ-protocadherin analytes (columns) over surfaces coated with the same set of proteins (rows).

Analyte concentrations of 27, 9, and 3  $\mu$ M are plotted on each panel. Responses are normalized for molecular weight and scaled for each surface, permitting comparison across rows only. Homophilic combinations are highlighted in green; heterophilic interactions within  $\delta$ 1- and  $\delta$ 2-subfamilies are boxed in teal and red. See Figure S1.

Protein δ1-family	Schematic	Oligomeric State	Monomer Mw (kDa) <sup>a</sup>	Apparent Mw (kDa) <sup>b</sup>	K <sub>D</sub> (μM)
	1000007				
Dis alla di	1000000				
Pcdh-1		dimer	95.7	$177 \pm 3.4$	$1.2 \pm 0.55^{\circ}$
Pcdh-7 <sub>mouse</sub> d	1000007	dimer	101.6	168 ± 4.9	8.2 ± 2.5
Pcdh-9	1000007	dimer	103.5	$204\pm3.7$	$2.03\pm0.43$
Pcdh-11 <sup>e</sup>	1000007	dimer	113.5	190 ± 1.4	$7.8\pm0.17$
δ2-family					
Pcdh-8	100006	monomer	78.7	83.1 ± 0.7	N/A
Pcdh-8 <sub>mouse</sub>	100006	monomer	79.4	$78.3\pm0.2$	N/A
Pcdh-8.1 <sub>Xenopus</sub>	100006	dimer	76.7	$134.7\pm5.9$	$3.5\pm2.4$
Pcdh-8.2 <sub>Xenopus</sub>	100006	dimer	76.6	$138.2\pm0.9$	$1.7\pm0.10$
Pcdh-10	100006	dimer	77.2	$134 \pm 2.0$	$3.6\pm0.61$
Pcdh-12	100006	dimer	78.8	$133 \pm 0.1$	$5.4\pm0.20$
Pcdh-17	100006	dimer	87.3	168 ± 4.9	$4.8\pm0.54$
Pcdh-18	100006	dimer	82.0	148 ± 2.8	$2.7\pm0.67$
Pcdh-19	100006	dimer	78.0	$139\pm3.8$	$0.48\pm0.10$
Fragments					
Pcdh-1 EC1–EC4	1004000	dimer	50.5	97.7 ± 2.2	$0.53\pm0.46$
Pcdh-7 EC1–EC4	1004000	dimer	56.5	104 ± 1.5	$2.70\pm1.0$
Pcdh-7 EC1–EC4 <sub>mouse</sub>	1004000	dimer	56.4	101 ± 1.4	4.1 ± 1.3
Pcdh-9 EC1–EC4	1004000	dimer	56.1	$104 \pm 1.5$	$2.0\pm0.52$
Pcdh-10 EC1-EC4	100400	dimer	50.2	$96.4\pm0.4$	$0.68\pm0.13$
Pcdh-1 EC1-EC3	1030000	monomer	35.9	$36.8\pm0.9$	N/A
Pcdh-10 EC1-EC3	103000	weak dimer	39.5	$45.8 \pm 1.4$	280 ± 110
Pcdh-1 EC5–EC7	0000507	monomer	47.1	$45.8\pm0.04$	N/A
Pcdh-10 EC5-EC6	000056	monomer	28.7	$29.4\pm0.2$	N/A
Pcdh-8 EC5–EC6	000056	monomer	26.9	$27.8\pm0.1$	N/A

Table 1. Dissociation Constants ( $K_D$ ) for Homodimerization of  $\delta$ -protocadherin Extracellular Regions and Fragments Determined by Analytical Ultracentrifugation

See also Figure S2.

<sup>a</sup>Average molecular weight determined from mass spectrometry peak maximum.

<sup>b</sup>Determined from AUC data using an ideal monomer model.

<sup>c</sup>Errors represent standard deviation from two or more experiments.

<sup>d</sup>All constructs derive from human except where stated.

<sup>e</sup>Pcdh11Y isoform is reported.

equilibria (Table 1). Complementary analyses using size exclusion chromatography with multi-angle light scattering (SEC-MALS) also showed single major elution peaks for each  $\delta$ -protocadherin with apparent molecular weights between monomer and dimer, supporting this interpretation (Figure S2). No evidence of higher-order oligomers (>dimer) was observed using either technique.

Fitting of the AUC data to monomer-dimer models yielded  $K_D$  values for homodimerization spanning the low micromolar range (Table 1).  $K_D$  values across both subfamilies differed over an  $\sim$ 20-fold range with no general trend separating  $\delta 1$  from  $\delta 2$ . Within the  $\delta 1$ -family, pcdh1 and -9 formed tighter homodimers relative to pcdh7 and -11 by  $\sim$ 4-fold (Table 1). In the  $\delta 2$ -subfamily,  $K_D$  values for most members were comparable within error

except for pcdh18, which formed modestly higher affinity dimers and pcdh19, which formed the highest affinity dimers observed in these experiments (Kp 0.48 µM, Table 1). While pcdh8 EC1-EC6 fragments from human and mouse both displayed impaired solubility, their soluble fractions behaved as apparent monomers in AUC and SEC-MALS analyses, suggesting the possibility that pcdh8 may not form dimers. However, we observed that fulllength human pcdh8 could induce cell aggregation in qualitative assays using transfected K562 cells (Figure S2), as reported previously for the mouse ortholog (Bisogni et al., 2018). We also found that the Xenopus ortholog of pcdh8, pcdh8.1 (MGC84237), and its paralog pcdh8.2 (PAPC) formed dimers in AUC (Table 1). Thus, human and mouse pcdh8 trans dimerization appears sufficient to produce measurable cell surface adhesion, but may have weak affinity below the threshold of detection in solution. Weak adhesion has been described previously for arcadlin, the rat ortholog of pcdh8, and its homophilic binding has been suggested to enhance endocytosis of N-cadherin rather than mediate stable adhesion (Yasuda et al., 2007); similar roles for mouse and human pcdh8 remain to be tested.

# $\delta$ 1- and $\delta$ 2-Protocadherins Adopt Canonical Antiparallel trans Dimers

The mechanism of  $\delta$ 2-protocadherin *trans* binding was revealed previously in a crystal structure of zebrafish pcdh19 EC1–EC4 (Cooper et al., 2016), which adopted an antiparallel *trans* dimer similar to clustered protocadherins (Goodman et al., 2016a, 2016b). Formation of a similar *trans* dimer by  $\delta$ 1-protocadherins was also reported in a recent crystal structure of human pcdh1 EC1–EC4 (Modak and Sotomayor, 2019), representing the same crystal form as that described here. To compare binding determinants across the  $\delta$ -protocadherin family, we determined EC1–EC4 fragment crystal structures of human pcdh1, -10 (two crystal forms), -17, -18, and -19, with resolutions 2.3–3.7 Å (Table S1).

In each of the six  $\delta$ -protocadherin structures (Figure 2), individual protomers adopted approximately linear arrangements of domains EC1-EC4 rigidified by coordination of three calcium ions in each interdomain linker, as is characteristic for the cadherin family. N-linked glycan moieties were observed in all structures and included conserved glycosylation of the B-strand of EC3 (e.g., Asn248 in pcdh1), suggesting possible biological significance. Additionally, O-linked glycans were observed on the EC2 G-strand in pcdh-10 and -17, corresponding to cadherinspecific O-mannosylation sites identified previously by mass spectrometry (Larsen et al., 2017). No glycans were significantly buried in protein-protein interfaces. Individual loops in pcdh10 (EC2 F-G loop) and pcdh17 (EC4 C-D loop) corresponding to glycine-rich insertions of 19 and 15 amino acids (Figure 2) not present in other  $\delta$ -protocadherins appeared disordered, and showed no interpretable electron density. The function of these loops remains to be determined, but they are distal from trans interface regions (see below), and are unlikely to directly modify binding.

Structures belonging to both the  $\delta 1$ - (pcdh1) and  $\delta 2$ - (pcdh-10, -17, -18, and -19) subfamilies contained antiparallel 2-fold symmetric or pseudosymmetric dimers in their crystal lattices (Figures 2A, 2C, and 2F). In addition to the dimer, pcdh10 also

crystallized in a monomeric crystal form (Figure 2B), likely due to low pH conditions in the crystallization experiment (see STAR Methods). Overall dimer arrangements were broadly similar for all structures, consistent with  $\delta$ 1- and  $\delta$ 2-family members forming trans dimers by the same general mechanism (Figure 2). Dimer topologies corresponded to those described for zebrafish pcdh19 (Cooper et al., 2016) and for clustered protocadherins (Goodman et al., 2016a, 2016b). Briefly, partner EC1–EC4 regions overlap fully in an antiparallel dimer stabilized by EC1:EC4 and EC2:EC3 interfaces on both sides of a 2-fold symmetry axis centered on the EC2-EC3 linker (Figure 2). EC1:EC4 interfaces form between the C-F-G face of EC1 and the A-B-E-D face of EC4 while EC2:EC3 interfaces form between the A-B-E-D face of EC2 and the C-F-G face of EC3 (Figure S3A). Symmetric EC3:EC3 contacts between paired FG loops form the center of the dimer where paired protomers cross (Figure S3A). In pcdh-1, -18, and -19, a disulfide-stabilized E-F loop in EC1 protrudes sufficiently to form additional minimal contacts with the E-F loop of the partner EC3 (Figure S3A). Buried surface areas (BSAs) for individual dimers (Table S2) ranged from 2,024 Å<sup>2</sup> (pcdh17) to 4,176 Å<sup>2</sup> (pcdh19). High BSA for pcdh19, in combination with a higher proportion of hydrophobic buried surface (70%, Table S2), likely underlies the strong homophilic affinity observed in AUC (see Table 1).

# Differences in Overall Dimer Arrangements among $\delta\text{-}$ Protocadherins

Despite conservation of overall dimer topology, differences in precise dimer orientation and interface loop conformations were observed between  $\delta$ -protocadherins. Dimers of pcdh-10, -18, and -19 superposed moderately well (Figures S3B and S3E, root mean square deviation (RMSD) 2.7–3.2 Å over 772–794 Ca) and were closest in conformation to the previously reported structure of zebrafish pcdh19 (Cooper et al., 2016; Figure S3E; 2.2 Å over 791 Ca between zebrafish and human pcdh19).

Pcdh17 adopted a markedly more parallel alignment of paired protomers (Figure S3B) with increased separation near the EC2–EC3 linker and a shifted EC1:EC4 interface (Figure S3). However, a packing interaction with a symmetry-related protomer observed in the pcdh17 crystal lattice would partially occlude a canonical EC1:EC4 interface, suggesting the unusual conformation of the overall dimer to likely be a result of crystal packing (Figure S4A).

δ1-family member pcdh1 also showed differences in dimer conformation compared to  $\delta$ 2-pcdh-10, -18, and -19, adopting a bent dimer conformation compared to the canonical arrangement (Figure S3B). This arises in part from a more acute interdomain angle between EC2 and EC3 (Figure S3C). Accompanying this deviation, domains EC2 and EC3 interacted less closely (Figures S3A and S3D) and contribute a reduced BSA of 652 Å<sup>2</sup> per dimer (22% of total) compared to 1,137–2,136 Å<sup>2</sup> (42%–66%) for pcdh-10, -18, and -19 (Table S2). In particular, while contacts near the base of EC2 were preserved, those near the top of the EC2:EC3 interface involving EC2 D-E and EC3 C-D loops were more distant or solvent-exposed in pcdh1 (Figures S3A and S3D). While additional structures of δ1-protocadherins will be required to determine if this dimer arrangement is general and




Figure 2. Structures of Adhesive EC1–EC4 Fragments of  $\delta$ 1- and  $\delta$ 2-Protocadherins

(A–F) Ribbon representations showing two orthogonal views (upper and lower panels) of human EC1–EC4 fragment structures of (A) pcdh1; (B) pcdh10 monomer; (C) pcdh10 dimer; (D) pcdh17; (E) pcdh18.; and (F) pcdh19.

Single *trans* dimers, formed between symmetry-related protomers (A) or in the crystallographic asymmetric unit (C–F) are shown. Interdomain calcium ions are shown as green spheres; N-linked and O-linked glycans as wheat and magenta spheres. See Figures S3 and S4 and Tables S1 and S2.

exclude the possibility that it results from crystal packing in our pcdh1 crystals, the subtle conformational differences could account in part for binding incompatibility between  $\delta$ 1- and  $\delta$ 2-protocadherins.

Local conformational differences in loops located in the dimer interface were also observed between  $\delta$ -protocadherin subtypes, suggesting small structural variations in interface regions could contribute to binding preferences (Figure S4C). Superposition of individual EC domains of pcdh-1, -10, -17, -18, and -19 (RMSD 0.5–2.5 Å over 58–105 aligned Ca) revealed differences in interfacial C-D, D-E, and F-G loops of EC1; the DE loop of EC2; the C-D

loop of EC3; and the A-strand and D-E loop of EC4 (Figure S4C). Notably, pcdh1 contains an extended D-E loop in EC1 (Figure S4C) whose additional length is conserved in the  $\delta$ 1-branch and could, in principle, stabilize the more open dimer conformation observed for pcdh1. As expected, close correspondence in domain structure between monomer and dimer crystal forms of pcdh10 was observed (RMSD 0.179–0.282 Å over 79–98 residues per domain), however, local shifts of the EC2 D-E loop (~4.9Å) and EC4 B-C loop (~1.2 Å) toward the partner protomer (Figure S4D) suggest the possibility of subtle conformational changes in these regions upon binding.

# Conserved and Variable Molecular Interactions in $\delta\mathchar`-$ Protocadherin trans Dimers

We compared molecular interactions in dimer structures of pcdh1, -10, -18, and -19 to identify conserved and variable regions. Those of pcdh17 (Figure S4B) were not compared due to the uncertain physiological relevance of the divergent dimer orientation observed in the structure.

#### **Conserved Interactions**

In all structures, the EC1:EC4 interface was centered on a small conserved interaction primarily between the G-strand of EC1 and B-strand of EC4 (Figure 3A). In the pcdh1 dimer, Leu94 in the EC1 G-strand closely contacts Leu359 in the partner EC4 B-strand, while surrounding residues Pro92 (EC1), and Ile335, Ala356, Ala388, and Phe400 (EC4) contribute additional contacts to form a small hydrophobic "core" interface (Figure 3A). An analogous hydrophobic region in 82-pcdh dimer structures (pcdh-10, -18, and -19) is centered on apposed residues Leu88/93/Ile91 and Leu362/354/349 corresponding to Leu94 and Leu359 in pcdh1 (Figures 3A and S5), and is surrounded by hydrophobic residues corresponding to Pro92 and Ala356 in pcdh-1 (e.g., Leu86 and Val359 in pcdh10) or specific to the δ2-branch (e.g., Val39, Phe81 in pcdh10). Central residues Leu94 and Leu359 (pcdh1 numbering) are highly conserved across the whole  $\delta$ -protocadherin family and most surrounding hydrophobic residues are conserved in character (Figure S5), as described previously (Cooper et al., 2016; Nicoludis et al., 2015; Nicoludis et al., 2016). Adjacent to the hydrophobic region in EC1, an acidic residue (Glu80 in pcdh1) is buried in the interface in all structures (Figure 3A), and is also conserved across all subtypes (Figure S5). In pcdh1, Glu80 forms a potential salt bridge with Arg333 in EC4, which is also conserved in other members of the *b*1-branch (Figures 3A and S5). Arg333 is not conserved in 82 sequences, instead, potential salt bridges with Glu80 were observed with non-equivalent residue positions (Arg356 and Arg351 in pcdh18 and -19) or were replaced by potential H-bonding interactions (pcdh10, Figure 3A).

No other regions of interface conservation across both  $\delta$ 1- and  $\delta$ 2-branches were observed, however, the base of the EC2:EC3 interface where EC2 A/B and EC3 G-strands interact contained an extensive conserved region specific to the 82-branch (Figure 3A). In each dimer, a conserved proline in EC2 (Pro318 in pcdh10) is symmetrically apposed with the equivalent proline in the partner molecule with a distance of 3.5–4.2 Å (Figure 3A). Above this, residues Asn319, Val321, Pro322, His324, and Lys326 in the EC3 G-strand are apposed with Ser226 in the EC2-EC3 linker and Thr122, Arg123, Phe124, and Pro125 in EC2 (Figure 3A, pcdh10 numbering). While there are variations in the distances between these apposed residues in the respective dimers (Figure 3A), they are conserved in character among pcdh-10, -12, -17, -18, and -19 (Figure S5), indicating their likely importance. In *b*1-protocadherins, most of these residue positions are variable and differ from those of **b2-sequences** (Figure S5), suggesting that part of the incompatibility between the two subfamilies may derive from mismatches in these regions. Variable Interactions

Outside the conserved regions described above, interfacial residues in the EC1:EC4 and EC2:EC3 interfaces are highly variable between  $\delta$ -protocadherin dimer structures (Figure 3) and are

thus likely to underlie homophilic binding specificities. Mapping of these onto molecular surfaces of representative  $\delta 1$ - and  $\delta 2$ -structures reveals variable regions distinct for each subfamily framing conserved sites (Figure 3B).

The periphery of the EC1:EC4 interface contains variable interface residues in both subfamilies (Figures 3 and S5), and may be particularly important for **b1** specificity since EC1:EC4 interactions predominate in the pcdh1 dimer structure (Table S2; Figure 3B). In pcdh1, apposed hydrophobic residues Pro92 (EC1) and Ala356 (EC4) extend the area of hydrophobic contact above the conserved region in the dimer structure (Figure 3A). Substitution of Ala356 for lysine in other  $\delta$ 1-family members pcdh9 and -11 suggests alternative interactions in these dimers, likely with nearby subtype-specific acidic residues at position 90 (Figure S5, pcdh1 numbering). Similarly, two intermolecular salt bridges below the conserved EC1:EC4 region in pcdh1, Glu96-Lys398 and Glu78-Lys396 (Figure 3A), are potentially conserved in pcdh7, but not in other  $\delta$ 1-protocadherins where the Glu96 position is a lysine (Figure S5). This would likely electrostatically clash with Lys398 in putative heterodimers, but may be accommodated in homodimers where residue 398 is a glutamine (pcdh9, -11) or glutamate (pcdh20). In 82-protocadherins, residues corresponding to the salt-bridge-forming pair Glu96-Arg398 in pcdh1 are also highly variable in character and engage in polar (pcdh10, -18) or hydrophobic (pcdh19) interactions, sugaesting they could contribute to homophilic preferences and to incompatibility between  $\delta$ 1- and  $\delta$ 2-subfamilies (Figure 3A). Other 82 EC1:EC4 variable interactions are also primarily located at the base of EC1, and involve residues Ser342, Ser344, and Thr345 (Figure 3A, pcdh10 numbering).

The EC2:EC3 interface in pcdh1 involves few close interactions, but apposed residues near the EC2–EC3 linker are nonetheless variable within the  $\delta$ 1-subfamily (Figures S3 and S5). Most strikingly, at the center of the pcdh1 dimer Thr307 interacts symmetrically with the equivalent residue of the partner molecule at a distance of 4.9 Å (Figure 3A). This residue is  $\delta$ 1-subtypespecific, with Gln, Ser, Leu, and Cys residues found in pcdh-7, -9, -11, and -20 (Figure S5). Differences in side-chain length and character would likely lead to steric and hydrophobic:hydrophilic mismatches that could destabilize putative heterodimers. Supporting this possibility, self-interacting central residues in clustered protocadherin *trans* dimers have been shown to strongly influence binding specificity in mutagenesis studies (Goodman et al., 2016a).

In  $\delta$ 2-protocadherins the more extensive EC2:EC3 interface is conserved near its base as described above, but subtype-specific contacts are observed at the top of the interface where EC2 D-E and EC3 C-D loops contact the partner domains (Figure 3). The EC2 D-E loop engages primarily in electrostatic interactions with the partner EC3 domain in pcdh18 and -19, including a potential salt bridge (Arg162–Glu294 in pcdh18; Arg160–Glu292 in pcdh19) that is also conserved by sequence in pcdh-8 and -17 (Figure S5). In pcdh10, however, hydrogenbonding interactions predominate in this region and both charged residues are substituted with glutamine (Gln157 and Gln308, Figure 3A). Pcdh12 contains a single substitution in the arginine position to glycine, suggesting alternative dimer packing for this subtype (Figure S5). Notably,  $\delta$ 1-protocadherins





Figure 3. Conserved and Variable Molecular Interactions in the trans Dimer Interface

(A) Residue views of interface regions EC1:EC4 (top) and EC2:EC3 (bottom) in *trans* dimers of pcdh-1, -10, -18, and -19 (left to right). Side chains of interfacial residues (>5% buried) are shown as sticks. Interactions conserved between multiple structures are highlighted in gold. Conserved hydrophobic residues chosen for mutation are boxed. Green spheres: calcium ions.

(B) Molecular surfaces of representative  $\delta1$  (pcdh1, left) and  $\delta2$  (pcdh10, right) *trans* dimer structures opened to display interfacial residues color-coded according to their conservation within the respective subfamily (yellow: conserved in character; magenta: variable). Non-interface residues are shown in gray. Half of each 2-fold symmetric dimer is shown for clarity.

See Figures S3-S5.



#### Figure 4. SPR Analysis of Targeted trans Interface Mutations

(A) Homophilic binding of wild-type and *trans* interface mutant  $\delta$ 1 EC1–EC4 fragments of pcdh-1, -7, and -9 over their respective wild-type surfaces.

(B) Effects of trans interface mutations in pcdh1 and -7 on heterophilic binding to pcdh-9 (left) and -11 (right).

(C) Homophilic binding of wild-type and *trans* interface mutants of  $\delta$ 2-pcdh-10, -12, -17, -18, and -19 over wild-type surfaces.

Three analyte concentrations (27, 9, and 3  $\mu$ M) are plotted and responses are scaled independently for each surface.

contain an arginine at the glutamate position (Arg297 in pcdh1), and the possibility that resulting electrostatic clashes could prevent binding between subfamilies has been discussed previously (Cooper et al., 2016). In EC3, C-D loops of pcdh-10, -17, and -18 share similar sequences (Figure S5) and conformations (Figure S4C), but that of pcdh19 adopts a subtly different conformation in the interface (Figures 3A and S4C), accommodating two pcdh19-specific interfacial aromatic residues (Tyr257 and Tyr259) that extend to form close contacts with EC2 and contribute to the more hydrophobic character of the pcdh19 interface.

#### Mutations in a Conserved Region of the EC1:EC4 Interface Abolish *trans* Binding

We next tested the effects of targeted point mutations on binding of EC1–EC4 fragments in SPR (Figure 4). While both EC1:EC4 and EC2:EC3 interface regions contribute substantial BSA (Table S2), we targeted the hydrophobic region of the EC1:EC4 interaction due to its family-wide conservation. Substitution of highly conserved residues Leu94 (EC1 side) or Leu359 (EC4 side) with lysine or aspartic acid ablated homophilic binding of pcdh1 (Figure 4A, L94K and L359D mutants). Equivalent EC4 mutations in pcdh7 (L414D) and pcdh9 (L362D) also ablated homophilic binding, consistent with involvement of the hydrophobic region throughout the  $\delta$ 1 family (Figure 4A). Heterophilic binding interactions between pcdh-7 and -9 or between pcdh-1 and -11 were also abolished by these mutations (Figure 4B), indicating that these form through the same interface.

In  $\delta$ 2-protocadherins, equivalent mutations had comparable effects: homophilic binding was ablated in pcdh10 (L88K and L362D), -12 (L346D), and -18 (L354D) and diminished in pcdh-17 (L356D) and -19 (L349D, Figure 4C). Inhibition of pcdh17 homophilic binding by mutation L356D suggests the interface likely adopts a more canonical conformation in solution than in the divergent crystal structure (Figure S4A), where Leu356 is

solvent-exposed (Figure S4B). Nevertheless, the incomplete inhibition may suggest weaker contribution of EC1:EC4 to pcdh17 binding that could permit crystallization in the non-canonical orientation observed. Pcdh19 L349D mutant showed the mildest diminution of comparative binding responses in SPR, likely reflecting maintenance of the dimer by the more extensive contacts observed in the dimer overall (Figure 3A; Table S2).

Together, the mutational data confirm the structurally observed dimer to be generally conserved across the  $\delta$ -protocadherin family and support previous suggestions that a hydrophobic "core" in the EC1:EC4 interface is a conserved characteristic of canonical protocadherin dimers (Cooper et al., 2016; Nicoludis et al., 2016; Rubinstein et al., 2015).

# $\delta\mbox{-}\mbox{Protocadherins}$ Do Not Form Higher Order Oligomers in Solution

Our AUC and SEC-MALS analyses of complete ectodomains revealed no evidence for oligomers larger than dimers for any  $\delta$ -protocadherin (Table 1; Figure S2). These observations for  $\delta$ -protocadherins contrast with comparable AUC analyses of clustered  $\beta$ -,  $\gamma$ B-, and C-type protocadherins for which tetramers were detected in solution (Goodman et al., 2016b; Rubinstein et al., 2015), formed by a combination of EC1–EC4-mediated *trans* interactions and EC5–EC6-mediated *cis* interactions (Goodman et al., 2016b). Thus, our data suggested that  $\delta$ -protocadherins, despite their overall similarity to the clustered branch (Hulpiau and van Roy, 2009), might lack comparable ectodomain-mediated *cis* interactions strong enough to be detected in solution.

To test further if membrane proximal EC5–EC7 ( $\delta$ 1) or EC5–EC6 ( $\delta$ 2) domains contributed to associations measured in solution, we analyzed a range of truncated fragments in AUC. C-terminally truncated fragments of pcdh1, -7, -9, and -10 encompassing EC1–EC4 showed homodimerization affinities comparable to or stronger than those of the full-length

ectodomains, indicating that EC5–EC6/7 domains do not enhance oligomerization of the longer fragments (Table 1). As expected, further truncation of pcdh1 and pcdh10 to EC1–EC3 to remove part of the *trans* binding EC1–EC4 region reduced homodimerization to very weak or undetectable levels (Table 1). Lastly, fragments containing only membrane-proximal regions, pcdh1 EC5–EC7, pcdh10 EC5–EC6, and pcdh8 EC5–EC6, were monomeric, consistent with an absence of strong EC5–EC6-mediated homophilic interactions (Table 1). Similar results were obtained for binding of the pcdh1 and pcdh10 fragments to respective full ectodomains in SPR (Figure S1C). Potential heterophilic interactions between membrane-proximal EC5–EC6 and EC5– EC7 fragments of pcdh-1, -8, and -10 fragments were also not detected when stoichiometric mixtures were assessed by SEC-MALS (Figure S2B).

# cis-interaction Signatures of Clustered Protocadherins Are Absent from $\delta\text{-Protocadherin}$ Membrane-Proximal Region Structures


The lack of detectable *cis* interactions in solution did not exclude the possibility that weaker associations below the threshold of detection of AUC experiments ( $K_D > \sim 1$  mM) could form. To investigate this, we characterized prospective *cis*-interaction regions in three additional  $\delta 2$  family structures: full ectodomains (EC1–EC6) of *Xenopus* pcdh8.1 and human pcdh10, and an EC5–EC6 fragment of human pcdh8 (Figure 5; Table S1).

Crystals of Xenopus pcdh8.1 and human pcdh10 ectodomains each showed highly anisotropic diffraction with resolution limits of 3.0/3.0/2.0 Å and 4.2/4.2/3.3 Å, respectively (Table S1). Both structures revealed an approximately linear overall arrangement of six EC domains including canonical calcium binding in all interdomain linkers (Figures 5A and 5B). Pcdh8.1 formed canonical trans dimers in the crystal lattice (Figure 5A), similar to those observed for human  $\delta$ 2-protocadherins, including close EC2:EC3 contacts and an EC1:EC4 interface centered on hydrophobic residues (Leu86 and Phe344) equivalent to Leu94 and Leu359 of pcdh1. Trans dimers were not observed in the pcdh10 EC1-EC6 crystal lattice (Figure 5B), likely due to acidic crystallization conditions (pH 5; see STAR Methods) similar to those of the monomeric EC1-EC4 fragment structure (Figure 2B). However, since our mutagenesis data showed that pcdh10 ectodomains likely form canonical trans dimers in solution (Figures 4C and S1C; Table 1), we used the EC1–EC4 trans dimer structure crystallized at neutral pH to model a full-length pcdh-10 trans dimer by superposition over domains EC1-EC4 (Figure 5C). The extended bow-like dimers for pcdh8.1 and pcdh10 show distances of 382 Å and 361 Å between paired C-termini, representing lower limits for predicted intermembrane spacing due to stalk regions of 24 (pcdh8.1) and 35 (pcdh10) amino acids preceding the predicted transmembrane regions that were not included in the crystallized constructs. Notably, neither pcdh8.1 nor pcdh10 EC1-EC6 crystal lattices revealed interfaces that could geometrically align protomers deriving from the same membrane surface in a cis orientation. A 2.9 Å resolution structure of human pcdh-8 EC5-EC6 also revealed canonical EC domain architecture and did not contain interfaces geometrically compatible with cis interactions (Figure 5D), in agreement with the monomeric nature of the EC5–EC6 fragment in AUC experiments (Table 1).

EC5-EC6 regions from human pcdh8 and pcdh10 structures superposed closely with the equivalent domains of clustered protocadherin yB7 EC3-EC6 (Goodman et al., 2017; RMSD 1.3–1.9 Å for 181–191 aligned  $C\alpha$ ; Figure 5E), allowing surface residue positions involved in the yB7 cis interface to be compared. Sequence alignment of residue positions whose side chains are buried in the  $\gamma$ B7 cis interface reveals seven positions with high conservation within  $\beta$ - and  $\gamma$ -clustered protocadherins but poor conservation in pcdh-8 and -10 and other  $\delta$ -protocadherins (Figures 5F and S6). Mapping the differentially conserved positions on the structure of the yB7 cis interface reveals them to constitute a large proportion of the core of the interaction (Figure 5G). Furthermore, these include residues Tyr532 and Val560, shown by mutagenesis to be critical for cis interactions of clustered protocadherins (Goodman et al., 2017, 2016b; Figure 5G). Together, poor conservation of cis interaction surfaces and lack of detectable cis oligomerization in solution suggest that the  $\delta$ -protocadherins do not assemble laterally through an interface comparable to that of clustered protocadherins.

# Assembly of $\delta$ 1- and $\delta$ 2-Protocadherin Ectodomains in Reconstituted Junctions

We recently showed, using cryo-electron tomography (cryo-ET), that clustered protocadherin yB6 ectodomains form distinctive zipper-like assemblies of alternating cis and trans interactions at contact sites between membranes (Brasch et al., 2019). We would expect such assemblies to be absent from  $\delta$ -protocadherin contacts based on the lack of *cis* interface conservation. We therefore visualized intermembrane adhesion by  $\delta$ 1- and  $\delta$ 2-protocadherins by attaching full ectodomains of pcdh1 ( $\delta$ 1family) or pcdh10 (82-family) to liposome surfaces via C-terminal hexahistidine tags. Initial fluorescence microscopy experiments using rhodamine-labeled liposomes showed extensive aggregation mediated by pcdh1 and pcdh10, which was abolished for trans interface mutants pcdh1 L359D and pcdh10 L362D (Figure 6A). We next visualized vitrified liposome aggregates by cryo-ET (Table S3). Tomographic reconstructions of pcdh1mediated aggregates (Figure 6B; Videos S1, S2, and S3) showed extensive junction-like structures between contacting liposomes, with flattening of apposed membranes and an intermembrane spacing of  $\sim$ 490 Å (Figure 6D). Dense accumulation of pcdh1 ectodomains protruding perpendicularly from both membranes was observed at these sites and a diffuse midline of increased density with a width of ~200 Å could be discerned (Figure 6B), corresponding closely to the predicted width of overlapped EC1-EC4 regions in trans dimers, where density would be expected to be doubled. Individual pcdh1 ectodomains were resolved within the junctions (Figures 6B and 6D) and on free membranes (Figure 6B) with elongated overall conformations, as expected. Broadly similar junction formation was observed for pcdh10, including flattening of apposed membranes and dense accumulation of ectodomains (Figures 6C and 6D; Videos S4 and S5). Intermembrane spacing was  $\sim$ 377 Å, narrower than pcdh1 junctions where ectodomains contain one extra EC domain (Figure 6D). Midlines and individual ectodomains were less clearly resolved for pcdh10, and junctions appeared less uniform than those of pcdh1 (Figure 6D).



#### Figure 5. Membrane-proximal Regions of $\delta$ 2-Protocadherins Lack *cis* Interface Signatures

(A and B) Crystal structures of *Xenopus* pcdh 8.1 EC1–EC6 (A) and human pcdh10 EC1–EC6 (B), shown as ribbons. Green spheres: calcium ions; wheat and magenta spheres: N- and O-linked glycans.

(C) Superposition of two molecules of pcdh10 EC1–EC6 (gold) over the trans dimer structure of pcdh10 EC1–EC4 (orange).


(D) Crystal structure of human pcdh8 EC5-EC6 membrane-proximal fragment, shown as ribbon.

(E) Superposition of EC5–EC6 membrane-proximal regions of pcdh8 (magenta) and pcdh10 (gold) over EC5–EC6 from clustered pcdh <sub>Y</sub>B7 (cyan, PDB: 5V5X; Goodman et al., 2017).

(F) Sequence logo plots of aligned mouse clustered protocadherins  $\beta$ ,  $\gamma A$ , and  $\gamma B$  (top) or human  $\delta$ -protocadherins (bottom). Only residue positions with side chains > 20% buried in the  $\gamma B7$  *cis* dimer (PDB: 5V5X) are shown. Positions conserved only in clustered protocadherinpcdhs are highlighted orange. Numbering refers to pcdh  $\gamma B7$ .

(G) Close-up view of the *cis* interface of clustered pcdh γB7 (Goodman et al., 2017) showing differentially conserved interface residues from (E). Protomers colored slate and cyan.

See Figure S6 and Table S1.



#### Figure 6. Assembly of $\delta\mbox{-Protocadherin Ectodomains in Reconstituted Liposome Junctions}$

(A) Fluorescence microscopy of liposome aggregation mediated by pcdh1 and pcdh10 ectodomains or *trans* dimer mutants pcdh1 L359D and pcdh10 L362D. Scale bar: 0.5 mm.

(B and C) Representative slices of reconstructed tomograms showing aggregated liposomes of pcdh1 (B) or pcdh10 (C). Protocadherin ectodomains enrich at liposome contact sites seen in "side views" (black arrowheads) where membranes appear parallel, and "top views" (arrows) where liposomes are stacked vertically. Unbound ectodomains protrude from non-junctional membranes (white arrowheads). See Videos S1, S2, S3, S4, and S5.

(D) Side views of pcdh1, pcdh10, and pcdh gB6 junctions showing ordered assembly only for pcdh gB6. Intensity plots below each image show intermembrane distances and shallow minima where *trans* dimers overlap (brackets). Lipid bilayers are indicated with dashed lines.

(E) Comparison of top views showing formation of a regular lattice by pcdh gB6 ectodomains only. Scale bars in (B)–(E): 400 Å. See Table S3.

Importantly, characteristic ellipsoidal views of zipper-like lattices observed previously for clustered protocadherin  $\gamma$ B6 (Figure 6D; Brasch et al., 2019) were absent from tomographic reconstructions of both pcdh1 and pcdh10 (Figures 6B-6D). Moreover, while the δ-protocadherin junctions contained high densities of closely packed trans dimers they appeared to lack regular periodicity in the intermembrane densities that would indicate overall lattice-like order. This was particularly evident in "top views" of junctions between liposomes stacked along the z axis, in which the lateral position in the membrane of each protocadherin molecule can be seen: no apparent order was observed for pcdh1 and pcdh10 in contrast to the ordered grid-like pattern for clustered pcdh γB6 (Figure 6E; Brasch et al., 2019). These findings suggest that cis interactions seen for clustered protocadherins are not formed by  $\delta$ -family protocadherins and, further, that their ectodomains may lack a propensity to organize into ordered structures between membranes.

#### DISCUSSION

Here we have biophysically and structurally characterized the ectodomain interactions of most typical members of the  $\delta$ 1and  $\delta 2$ -protocadherin families. While  $\delta$ -protocadherins are highly similar to the clustered protocadherins, they exhibit specific differences that likely relate to their distinct biological roles. The clustered,  $\delta$ 1-, and  $\delta$ 2-protocadherin families bind in *trans* through topologically similar antiparallel EC1-EC4 dimers, each composed of two large EC1:EC4 and EC2:EC3 and one small EC3:EC3 interface region. This binding mode has been well characterized for the clustered protocadherins (Goodman et al., 2016a, 2016b) and for S2-family member Pcdh19 from zebrafish (Cooper et al., 2016), while structures of pcdh1 reported here and in Modak and Sotomayor (2019) extend the mechanism to the  $\delta$ 1-family. Despite topological similarity overall, we observed no cross-family interactions between  $\delta 1$ -,  $\delta 2$ -, and clustered protocadherins, likely reflecting differences in interface orientations and residue conservation. This "orthogonal" subfamily specificity resembles that observed previously between type I and type II classical cadherins (Katsamba et al., 2009) and may allow different subfamilies to establish overlapping but independent sets of adhesive cues. In  $\delta$ 1- and  $\delta$ 2-protocadherins, orthogonal specificity may derive from differences in preferred sub-interface orientations, though additional structures of *b1*-family trans dimers will be necessary to establish that differences observed for pcdh1 are maintained for other subtypes. Additional incompatibility may derive from residue differences in the central EC3:EC3 interaction; the base of the EC2:EC3 interface that is conserved in  $\delta 2$  only; and in the DE loop of EC2, where electrostatic clashes between some subtypes may arise, as noted previously (Cooper et al., 2016).

Within the  $\delta$ 1- and  $\delta$ 2-subfamilies, *trans*-binding specificities revealed in our SPR experiments are primarily homophilic, in agreement with cell aggregation studies (Bisogni et al., 2018; Pederick et al., 2018; Tai et al., 2010) and consistent with the homophilic cell sorting role uncovered for pcdh19 *in vivo* (Pederick et al., 2018). In addition, we detect substantial heterophilic binding among members of each subfamily. Overall, this specificity pattern is similar to those of the type I and type II classical cadherin families that function primarily in adhesion. Type I cadherins (including E-, N-, and P-cadherins) have highest trans-binding strength with self in most cases, but show significant cross-interactions with other family members (Katsamba et al., 2009; Vendome et al., 2014), while type II cadherins display extensive heterophilic interactions that frequently exceed homophilic binding (Brasch et al., 2018). Homophilic preference is more uniform for  $\delta$ -protocadherins where homophilic SPR responses were strongest for all subtypes tested, potentially explaining the absence of detectable heterotypic aggregates between cells transfected with different single δ-protocadherins (Bisogni et al., 2018; Pederick et al., 2018). Nonetheless, heterophilic responses observed in the  $\delta$ 1-family approach those of homophilic responses, suggesting likely physiological relevance. The limited heterophilic responses observed between  $\delta$ 2-protocadherins produced far lower responses than homophilic binding, and thus their physiological significance is less clear. Heterophilic interactions, commonly found for protein families that function primarily in adhesion, can play a role at boundaries between different cell types sharing a single family member (Basu et al., 2018; Brasch et al., 2018; Generous et al., 2019; Labernadie et al., 2017; Togashi et al., 2011; Volk et al., 1987), or in refining celllevel interaction specificity when co-expressed (Carrillo et al., 2015; Cosmanescu et al., 2018; Patel et al., 2006; Xu et al., 2018). As described above, δ-protocadherins are often coexpressed in the same cell (Etzrodt et al., 2009), and effects of δ-protocadherin co-expression on cell-interaction specificity have been demonstrated in cell aggregation experiments (Bisogni et al., 2018: Pederick et al., 2018).

Outside of the trans-binding mechanism, we identified significant differences between  $\delta$ - and clustered protocadherins. Clustered protocadherins are thought to emanate from the plasma membrane as cis dimers mediated by their membrane-proximal EC5 and EC6 domains (Goodman et al., 2017). Their ectodomains have been shown to form tetramers in solution ( $\gamma B$ -,  $\beta$ -, and C-type; Goodman et al., 2016b; Rubinstein et al., 2015) and to assemble zipper-like structures of alternating cis and trans interactions in crystal structures and between membranes (pcdh  $\gamma$ B4 and  $\gamma$ B6; Brasch et al., 2019). By contrast,  $\delta$ -protocadherin ectodomains form no detectable cis interactions in AUC, SPR, and SEC-MALS experiments (Table 1; Figures S1C and S2). We also observe no evidence for cis interactions in crystal structures of 82-protocadherin full ectodomains or membrane-proximal regions (Figure 5) and canonical cis interface regions are poorly conserved (Figure 5), arguing against the possibility of weaker cis interactions not detectable in solution as observed for E-, N-, and C-cadherins (Harrison et al., 2011). More definitively, tomograms of reconstituted junctions formed by representative members of the  $\delta$ 1- and  $\delta$ 2-families display structures that lack evidence of ordered lattices or zippers and appear instead to be characteristic of adhesion proteins engaged only in *trans* interactions (Figure 6).

Lack of *cis*-dimerization is consistent with functional differences between clustered and  $\delta$ -protocadherins. The clustered protocadherins, among other functions, encode diverse single-cell identities for some neuron types that underlie

self-avoidance (Kostadinov and Sanes, 2015; Lefebvre et al., 2012; Molumby et al., 2017; Mountoufaris et al., 2017; Zipursky and Grueber, 2013). We previously proposed that, despite comprising only 58 isoforms, co-expressed clustered protocadherins can encode sufficient diversity by engaging in *cis* and *trans* interactions to polymerize a zipper-like structure between dendrites from the same neuron to signal repulsion, which would be terminated by isoform mismatches with non-self-dendrites (Brasch et al., 2019; Rubinstein et al., 2015). We suggest here that this mechanism, which critically depends on *cis* dimerization, represents a clustered protocadherin-specific adaptation to provide the diversity for self-avoidance that did not arise in  $\delta$ -protocadherins, which are not thought to participate in this process.

Notably, there is previous evidence for some form of *cis* interaction between  $\delta$ -protocadherins from experiments demonstrating co-immunoprecipitation of pcdh19 with pcdh10 and pcdh17 in co-transfected K562 cells (Pederick et al., 2018). Since these experiments involved full-length proteins, these interactions may represent associations between transmembrane or cytoplasmic domains, either direct or indirect, which our data for extracellular regions do not exclude.

Functional roles of δ-protocadherins are coming into view with increasing clarity. The remarkable cell patterns that arise in GCE through X-linked inheritance of inactive forms of the Pcdh19 gene leaves little doubt that it plays an important role in cell adhesion (Pederick et al., 2018). δ-protocadherins also display expression patterns that differentially track tissue structures (Etzrodt et al., 2009; Redies et al., 2005), and for which changes in expression often precede the emergence of anatomical features in development (Redies et al., 2005; Roy and Bandyopadhyay, 2014). Phenotypes potentially related to adhesion have been found for numerous other  $\delta$ -protocadherins, as well (Bononi et al., 2008; Cooper et al., 2015; Hayashi et al., 2014; Hayashi and Takeichi, 2015; Hoshina et al., 2013; Uemura et al., 2007; Zhu et al., 2014). Overall, these observations are consistent with a common role in cell-cell adhesion and, indeed, we have shown that the trans-binding properties of  $\delta$ -protocadherins are similar to those of other families of adhesion proteins. Further, our data suggest that non-clustered protocadherins diverge from their clustered relatives in lacking specialized higher-order extracellular assemblies mediated by their ectodomains. Mechanisms linking *trans* binding of  $\delta$ -protocadherins to their cellular signaling functions remain to be elucidated.

#### **STAR**\*METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  METHOD DETAILS
  - Cloning and expression of recombinant proteins
  - SPR binding experiments
  - Analytical ultracentrifugation

- Size-exclusion chromatography with multi-angle light scattering (SEC-MALS)
- K562 cell aggregation assays
- O Protein crystallization and structure determination
- Sequence analysis
- Liposome aggregation assay and sample preparation for cryo-ET experiments
- Tilt-series data collection and processing
- Intermembrane distance measurements
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND CODE AVAILABILITY

#### SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j. celrep.2020.02.003.

#### ACKNOWLEDGMENTS

We thank SEMC OPs for technical support at the microscopes. Clustered protocadherins were provided by Seetha Mannepalli, Fabiana Bahna, and Kerry Goodman. D. Neau, S. Banerjee, I. Kourinov, and S. Narayanasami helped with data collection at the APS NE-CAT 24-ID-C/-E beamlines, supported by the National Institutes of Health (NIH) (grant P41GM103403). We acknowledge support from the National Science Foundation (grant MCB-1914542 to B.H.) and NIH (grants R01MH114817 and R01GM118584 to L.S.; F32GM128303 to A.J.N.; and R01DK106548 to R.V.S.). cryo-ET was performed at the Simons Electron Microscopy Center (SEMS) and the National Resource for Automated Molecular Microscopy at the New York Structural Biology Center, supported by the Simons Foundation (grant SF349247), NYSTAR, and NIH (grant GM103310).

#### **AUTHOR CONTRIBUTIONS**

O.J.H., J.B., and L.S. designed experiments. O.J.H. and J.B. cloned, expressed, and purified proteins and performed crystallography experiments. P.S.K. performed SPR experiments. G.A. performed AUC experiments. J.B. and A.J.N. performed liposome assays and cryo-ET. A.J.N. collected tilt-series. J.B. processed the tomograms. C.S.P. and B.C. supervised the cryo-ET. H.B. performed and R.V.S. supervised cell aggregation assays. B.H. and L.S. supervised the project. O.J.H., J.B., and L.S. wrote the manuscript. O.J.H., J.B., A.J.N., C.S.P., B.C., B.H., and L.S. edited the manuscript.

#### **DECLARATION OF INTERESTS**

The authors declare no competing interests.

Received: August 17, 2019 Revised: November 2, 2019 Accepted: January 31, 2020 Published: February 25, 2020

#### REFERENCES

Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.-W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221.

Afonine, P.V., Grosse-Kunstleve, R.W., Echols, N., Headd, J.J., Moriarty, N.W., Mustyakimov, M., Terwilliger, T.C., Urzhumtsev, A., Zwart, P.H., and Adams, P.D. (2012). Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. *68*, 352–367.

Agulleiro, J.I., and Fernandez, J.J. (2011). Fast tomographic reconstruction on multicore computers. Bioinformatics *27*, 582–583.

Agulleiro, J.-I., and Fernandez, J.-J. (2015). Tomo3D 2.0—exploitation of advanced vector extensions (AVX) for 3D reconstruction. J. Struct. Biol. *189*, 147–152.

Almagro Armenteros, J.J., Tsirigos, K.D., Sønderby, C.K., Petersen, T.N., Winther, O., Brunak, S., von Heijne, G., and Nielsen, H. (2019). SignalP 5.0 improves signal peptide predictions using deep neural networks. Nat. Bio-technol. *37*, 420–423.

Baldi, L., Hacker, D.L., Meerschman, C., and Wurm, F.M. (2012). Large-scale transfection of mammalian cells. Methods in Molecular Biology *801*, 13–26.

Barat, B., and Wu, A.M. (2007). Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum. Biomol. Eng. *24*, 283–291.

Barouch, D.H., Yang, Z.Y., Kong, W.P., Korioth-Schmitz, B., Sumida, S.M., Truitt, D.M., Kishko, M.G., Arthur, J.C., Miura, A., Mascola, J.R., et al. (2005). A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. *79*, 8828–8834.

Basu, R., Duan, X., Taylor, M.R., Martin, E.A., Muralidhar, S., Wang, Y., Gangi-Wellman, L., Das, S.C., Yamagata, M., West, P.J., et al. (2018). Heterophilic type II cadherins are required for high-magnitude synaptic potentiation in the hippocampus. Neuron *98*, 658–668.

Bisogni, A.J., Ghazanfar, S., Williams, E.O., Marsh, H.M., Yang, J.Y., and Lin, D.M. (2018). Tuning of delta-protocadherin adhesion through combinatorial diversity. eLife 7, e41050.

Blevins, C.J., Emond, M.R., Biswas, S., and Jontes, J.D. (2011). Differential expression, alternative splicing, and adhesive properties of the zebrafish  $\delta$ 1-protocadherins. Neuroscience *199*, 523–534.

Bononi, J., Cole, A., Tewson, P., Schumacher, A., and Bradley, R. (2008). Chicken protocadherin-1 functions to localize neural crest cells to the dorsal root ganglia during PNS formation. Mech. Dev. *125*, 1033–1047.

Brasch, J., Goodman, K.M., Noble, A.J., Rapp, M., Mannepalli, S., Bahna, F., Dandey, V.P., Bepler, T., Berger, B., Maniatis, T., et al. (2019). Visualization of clustered protocadherin neuronal self-recognition complexes. Nature *569*, 280–283.

Brasch, J., Harrison, O.J., Honig, B., and Shapiro, L. (2012). Thinking outside the cell: how cadherins drive adhesion. Trends Cell Biol. *22*, 299–310.

Brasch, J., Katsamba, P.S., Harrison, O.J., Ahlsén, G., Troyanovsky, R.B., Indra, I., Kaczynska, A., Kaeser, B., Troyanovsky, S., Honig, B., and Shapiro, L. (2018). Homophilic and heterophilic interactions of type II cadherins identify specificity groups underlying cell-adhesive behavior. Cell Rep. 23, 1840–1852.

Carrillo, R.A., Özkan, E., Menon, K.P., Nagarkar-Jaiswal, S., Lee, P.T., Jeon, M., Birnbaum, M.E., Bellen, H.J., Garcia, K.C., and Zinn, K. (2015). Control of synaptic connectivity by a network of Drosophila IgSF cell surface proteins. Cell *163*, 1770–1782.

Cole, J.L., Lary, J.W., P Moody, T., and Laue, T.M. (2008). Analytical ultracentrifugation: sedimentation velocity and sedimentation equilibrium. Methods Cell Biol. *84*, 143–179.

Cooper, S.R., Emond, M.R., Duy, P.Q., Liebau, B.G., Wolman, M.A., and Jontes, J.D. (2015). Protocadherins control the modular assembly of neuronal columns in the zebrafish optic tectum. J. Cell Biol. *211*, 807–814.

Cooper, S.R., Jontes, J.D., and Sotomayor, M. (2016). Structural determinants of adhesion by protocadherin-19 and implications for its role in epilepsy. eLife 5, e18529.

Corpet, F. (1988). Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. *16*, 10881–10890.

Cosmanescu, F., Katsamba, P.S., Sergeeva, A.P., Ahlsen, G., Patel, S.D., Brewer, J.J., Tan, L., Xu, S., Xiao, Q., Nagarkar-Jaiswal, S., et al. (2018). Neuron-subtype-specific expression, interaction affinities, and specificity determinants of DIP/Dpr cell recognition proteins. Neuron *100*, 1385–1400.

Crooks, G.E., Hon, G., Chandonia, J.-M., and Brenner, S.E. (2004). WebLogo: a sequence logo generator. Genome Res. *14*, 1188–1190.

Dereeper, A., Guignon, V., Blanc, G., Audic, S., Buffet, S., Chevenet, F., Dufayard, J.F., Guindon, S., Lefort, V., Lescot, M., et al. (2008). Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res. 36, W465-W469.

Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501.

Etzrodt, J., Krishna-K, K., and Redies, C. (2009). Expression of classic cadherins and delta-protocadherins in the developing ferret retina. BMC Neurosci. *10*, 153.

Evans, P.R., and Murshudov, G.N. (2013). How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204–1214.

Gaitan, Y., and Bouchard, M. (2006). Expression of the delta-protocadherin gene Pcdh19 in the developing mouse embryo. Gene Expr. Patterns *6*, 893–899.

Generous, A.R., Harrison, O.J., Troyanovsky, R.B., Mateo, M., Navaratnarajah, C.K., Donohue, R.C., Pfaller, C.K., Alekhina, O., Sergeeva, A.P., Indra, I., et al. (2019). *Trans*-endocytosis elicited by nectins transfers cytoplasmic cargo, including infectious material, between cells. J. Cell Sci. *132*, e235507.

Goodman, K.M., Rubinstein, R., Dan, H., Bahna, F., Mannepalli, S., Ahlsén, G., Aye Thu, C., Sampogna, R.V., Maniatis, T., Honig, B., and Shapiro, L. (2017). Protocadherin *cis*-dimer architecture and recognition unit diversity. Proc. Natl. Acad. Sci. USA *114*, E9829–E9837.

Goodman, K.M., Rubinstein, R., Thu, C.A., Bahna, F., Mannepalli, S., Ahlsén, G., Rittenhouse, C., Maniatis, T., Honig, B., and Shapiro, L. (2016a). Structural basis of diverse homophilic recognition by clustered  $\alpha$ - and  $\beta$ -protocadherins. Neuron *90*, 709–723.

Goodman, K.M., Rubinstein, R., Thu, C.A., Mannepalli, S., Bahna, F., Ahlsén, G., Rittenhouse, C., Maniatis, T., Honig, B., and Shapiro, L. (2016b). γ-Protocadherin structural diversity and functional implications. eLife *5*, e20930.

Grant, T., and Grigorieff, N. (2015). Measuring the optimal exposure for single particle cryo-EM using a 2.6 Å reconstruction of rotavirus VP6. eLife 4, e06980.

Harrison, O.J., Brasch, J., Lasso, G., Katsamba, P.S., Ahlsen, G., Honig, B., and Shapiro, L. (2016). Structural basis of adhesive binding by desmocollins and desmogleins. Proc. Natl. Acad. Sci. USA *113*, 7160–7165.

Harrison, O.J., Jin, X., Hong, S., Bahna, F., Ahlsen, G., Brasch, J., Wu, Y., Vendome, J., Felsovalyi, K., Hampton, C.M., et al. (2011). The extracellular architecture of adherens junctions revealed by crystal structures of type I cadherins. Structure *19*, 244–256.

Hayashi, S., Inoue, Y., Kiyonari, H., Abe, T., Misaki, K., Moriguchi, H., Tanaka, Y., and Takeichi, M. (2014). Protocadherin-17 mediates collective axon extension by recruiting actin regulator complexes to interaxonal contacts. Dev. Cell *30*, 673–687.

Hayashi, S., and Takeichi, M. (2015). Emerging roles of protocadherins: from self-avoidance to enhancement of motility. J. Cell Sci. *128*, 1455–1464.

Hoshina, N., Tanimura, A., Yamasaki, M., Inoue, T., Fukabori, R., Kuroda, T., Yokoyama, K., Tezuka, T., Sagara, H., Hirano, S., et al. (2013). Protocadherin 17 regulates presynaptic assembly in topographic corticobasal ganglia circuits. Neuron 78, 839–854.

Hulpiau, P., and van Roy, F. (2009). Molecular evolution of the cadherin superfamily. Int. J. Biochem. Cell Biol. *41*, 349–369.

Kabsch, W. (2010). XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132.

Kahr, I., Vandepoele, K., and van Roy, F. (2013). delta-Protocadherins in health and disease. Prog. Mol. Biol. Transl. Sci. *116*, 169–192.

Katsamba, P., Carroll, K., Ahlsen, G., Bahna, F., Vendome, J., Posy, S., Rajebhosale, M., Price, S., Jessell, T.M., Ben-Shaul, A., et al. (2009). Linking molecular affinity and cellular specificity in cadherin-mediated adhesion. Proc. Natl. Acad. Sci. USA *106*, 11594–11599.

Kim, S.Y., Chung, H.S., Sun, W., and Kim, H. (2007). Spatiotemporal expression pattern of non-clustered protocadherin family members in the developing rat brain. Neuroscience *147*, 996–1021.

Kim, S.Y., Yasuda, S., Tanaka, H., Yamagata, K., and Kim, H. (2011). Non-clustered protocadherin. Cell Adhes. Migr. 5, 97–105.

Kostadinov, D., and Sanes, J.R. (2015). Protocadherin-dependent dendritic self-avoidance regulates neural connectivity and circuit function. eLife *4*, e08964.

Kremer, J.R., Mastronarde, D.N., and McIntosh, J.R. (1996). Computer visualization of three-dimensional image data using IMOD. J. Struct. Biol. *116*, 71–76.

Krissinel, E., and Henrick, K. (2007). Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. *372*, 774–797.

Labernadie, A., Kato, T., Brugués, A., Serra-Picamal, X., Derzsi, S., Arwert, E., Weston, A., González-Tarragó, V., Elosegui-Artola, A., Albertazzi, L., et al. (2017). A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat. Cell Biol. *19*, 224–237.

Lander, G.C., Stagg, S.M., Voss, N.R., Cheng, A., Fellmann, D., Pulokas, J., Yoshioka, C., Irving, C., Mulder, A., Lau, P.-W., et al. (2009). Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. *166*, 95–102.

Larsen, I.S.B., Narimatsu, Y., Joshi, H.J., Siukstaite, L., Harrison, O.J., Brasch, J., Goodman, K.M., Hansen, L., Shapiro, L., Honig, B., et al. (2017). Discovery of an O-mannosylation pathway selectively serving cadherins and protocadherins. Proc. Natl. Acad. Sci. USA *114*, 11163–11168.

Lefebvre, J.L., Kostadinov, D., Chen, W.V., Maniatis, T., and Sanes, J.R. (2012). Protocadherins mediate dendritic self-avoidance in the mammalian nervous system. Nature *488*, 517–521.

Leung, L.C., Urbančič, V., Baudet, M.L., Dwivedy, A., Bayley, T.G., Lee, A.C., Harris, W.A., and Holt, C.E. (2013). Coupling of NF-protocadherin signaling to axon guidance by cue-induced translation. Nat. Neurosci. *16*, 166–173.

Light, S.E.W., and Jontes, J.D. (2017).  $\delta\mbox{-}Protocadherins: organizers of neural circuit assembly. Semin. Cell Dev. Biol. 69, 83–90.$ 

Lin, J., Wang, C., and Redies, C. (2012). Expression of delta-protocadherins in the spinal cord of the chicken embryo. J. Comp. Neurol. *520*, 1509–1531.

McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Cryst. *40*, 658–674.

Meng, W., and Takeichi, M. (2009). Adherens junction: molecular architecture and regulation. Cold Spring Harb. Perspect. Biol. 1, a002899.

Modak, D., and Sotomayor, M. (2019). Identification of an adhesive interface for the non-clustered delta1 protocadherin-1 involved in respiratory diseases. Commun. Biol. 2, 354.

Molumby, M.J., Anderson, R.M., Newbold, D.J., Koblesky, N.K., Garrett, A.M., Schreiner, D., Radley, J.J., and Weiner, J.A. (2017). γ-Protocadherins interact with neuroligin-1 and negatively regulate dendritic spine morphogenesis. Cell Rep. *18*, 2702–2714.

Molumby, M.J., Keeler, A.B., and Weiner, J.A. (2016). Homophilic protocadherin cell–cell interactions promote dendrite complexity. Cell Rep. *15*, 1037–1050.

Morishita, H., and Yagi, T. (2007). Protocadherin family: diversity, structure, and function. Curr. Opin. Cell Biol. *19*, 584–592.

Mountoufaris, G., Canzio, D., Nwakeze, C.L., Chen, W.V., and Maniatis, T. (2018). Writing, reading, and translating the clustered protocadherin cell surface recognition code for neural circuit assembly. Annu. Rev. Cell Dev. Biol. *34*, 471–493.

Mountoufaris, G., Chen, W.V., Hirabayashi, Y., O'Keeffe, S., Chevee, M., Nwakeze, C.L., Polleux, F., and Maniatis, T. (2017). Multicluster Pcdh diversity is required for mouse olfactory neural circuit assembly. Science 356, 411–414.

Nicoludis, J.M., Lau, S.-Y., Schärfe, C.P., Marks, D.S., Weihofen, W.A., and Gaudet, R. (2015). Structure and sequence analyses of clustered protocadherins reveal antiparallel interactions that mediate homophilic specificity. Structure *23*, 2087–2098.

Nicoludis, J.M., Vogt, B.E., Green, A.G., Schärfe, C.P., Marks, D.S., and Gaudet, R. (2016). Antiparallel protocadherin homodimers use distinct affinity- and specificity-mediating regions in cadherin repeats 1-4. eLife *5*, e18449. Noble, A.J., and Stagg, S.M. (2015). Automated batch fiducial-less tilt-series alignment in Appion using Protomo. J. Struct. Biol. *192*, 270–278.

Painter, J., and Merritt, E.A. (2006). Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. *62*, 439–450.

Patel, S.D., Ciatto, C., Chen, C.P., Bahna, F., Rajebhosale, M., Arkus, N., Schieren, I., Jessell, T.M., Honig, B., Price, S.R., and Shapiro, L. (2006). Type II cadherin ectodomain structures: implications for classical cadherin specificity. Cell *124*, 1255–1268.

Pederick, D.T., Richards, K.L., Piltz, S.G., Kumar, R., Mincheva-Tasheva, S., Mandelstam, S.A., Dale, R.C., Scheffer, I.E., Gecz, J., Petrou, S., et al. (2018). Abnormal cell sorting underlies the unique X-linked inheritance of PCDH19 epilepsy. Neuron *97*, 59–66 e55.

Redies, C., Vanhalst, K., and Roy, Fv. (2005). delta-Protocadherins: unique structures and functions. Cell. Mol. Life Sci. 62, 2840–2852.

Rich, R.L., and Myszka, D.G. (2007). Survey of the year 2006 commercial optical biosensor literature. J. Mol. Recognit. *20*, 300–366.

Robert, X., and Gouet, P. (2014). Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, W320–W324.

Roy, P., and Bandyopadhyay, A. (2014). Spatio-temporally restricted expression of cell adhesion molecules during chicken embryonic development. PLoS ONE 9, e96837.

Rubinstein, R., Goodman, K.M., Maniatis, T., Shapiro, L., and Honig, B. (2017). Structural origins of clustered protocadherin-mediated neuronal barcoding. Semin. Cell Dev. Biol. 69, 140–150.

Rubinstein, R., Thu, C.A., Goodman, K.M., Wolcott, H.N., Bahna, F., Mannepalli, S., Ahlsen, G., Chevee, M., Halim, A., Clausen, H., et al. (2015). Molecular logic of neuronal self-recognition through protocadherin domain interactions. Cell *163*, 629–642.

Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682.

Suloway, C., Pulokas, J., Fellmann, D., Cheng, A., Guerra, F., Quispe, J., Stagg, S., Potter, C.S., and Carragher, B. (2005). Automated molecular microscopy: the new Leginon system. J. Struct. Biol. *151*, 41–60.

Suloway, C., Shi, J., Cheng, A., Pulokas, J., Carragher, B., Potter, C.S., Zheng, S.Q., Agard, D.A., and Jensen, G.J. (2009). Fully automated, sequential tilt-series acquisition with Leginon. J. Struct. Biol. *167*, 11–18.

Tai, K., Kubota, M., Shiono, K., Tokutsu, H., and Suzuki, S.T. (2010). Adhesion properties and retinofugal expression of chicken protocadherin-19. Brain Res. *1344*, 13–24.

Terwilliger, T.C., Grosse-Kunstleve, R.W., Afonine, P.V., Moriarty, N.W., Zwart, P.H., Hung, L.W., Read, R.J., and Adams, P.D. (2008). Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr. D Biol. Crystallogr. *64*, 61–69.

Thu, C.A., Chen, W.V., Rubinstein, R., Chevee, M., Wolcott, H.N., Felsovalyi, K.O., Tapia, J.C., Shapiro, L., Honig, B., and Maniatis, T. (2014). Single-cell identity generated by combinatorial homophilic interactions between  $\alpha$ ,  $\beta$ , and  $\gamma$  protocadherins. Cell *158*, 1045–1059.

Togashi, H., Kominami, K., Waseda, M., Komura, H., Miyoshi, J., Takeichi, M., and Takai, Y. (2011). Nectins establish a checkerboard-like cellular pattern in the auditory epithelium. Science 333, 1144–1147.

Uemura, M., Nakao, S., Suzuki, S.T., Takeichi, M., and Hirano, S. (2007). OL-Protocadherin is essential for growth of striatal axons and thalamocortical projections. Nat. Neurosci. *10*, 1151–1159.

Vanhalst, K., Kools, P., Staes, K., van Roy, F., and Redies, C. (2005). delta-Protocadherins: a gene family expressed differentially in the mouse brain. Cell. Mol. Life Sci. *62*, 1247–1259.

Vendome, J., Felsovalyi, K., Song, H., Yang, Z., Jin, X., Brasch, J., Harrison, O.J., Ahlsen, G., Bahna, F., Kaczynska, A., et al. (2014). Structural and energetic determinants of adhesive binding specificity in type I cadherins. Proc. Natl. Acad. Sci. USA *111*, E4175–E4184.

Volk, T., Cohen, O., and Geiger, B. (1987). Formation of heterotypic adherenstype junctions between L-CAM-containing liver cells and A-CAM-containing lens cells. Cell 50, 987–994.

Whelan, S., and Goldman, N. (2001). A general empirical model of protein evolution derived from multiple protein families using a maximum-likelihood approach. Mol. Biol. Evol. *18*, 691–699.

Winkler, H., and Taylor, K.A. (2006). Accurate marker-free alignment with simultaneous geometry determination and reconstruction of tilt series in electron tomography. Ultramicroscopy *106*, 240–254.

Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., et al. (2011). Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. *67*, 235–242.

Xu, S., Xiao, Q., Cosmanescu, F., Sergeeva, A.P., Yoo, J., Lin, Y., Katsamba, P.S., Ahlsen, G., Kaufman, J., Linaval, N.T., et al. (2018). Interactions between

the Ig-superfamily proteins DIP- $\alpha$  and Dpr6/10 regulate assembly of neural circuits. Neuron *100*, 1369–1384, e1366.

Yasuda, S., Tanaka, H., Sugiura, H., Okamura, K., Sakaguchi, T., Tran, U., Takemiya, T., Mizoguchi, A., Yagita, Y., Sakurai, T., et al. (2007). Activityinduced protocadherin arcadlin regulates dendritic spine number by triggering N-cadherin endocytosis via TAO2beta and p38 MAP kinases. Neuron *56*, 456–471.

Zheng, S.Q., Palovcak, E., Armache, J.-P., Verba, K.A., Cheng, Y., and Agard, D.A. (2017). MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods *14*, 331–332.

Zhu, P., Lv, J., Yang, Z., Guo, L., Zhang, L., Li, M., Han, W., Chen, X., Zhuang, H., and Lu, F. (2014). Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. *452*, 567–574.

Zipursky, S.L., and Grueber, W.B. (2013). The molecular basis of self-avoidance. Annu. Rev. Neurosci. *36*, 547–568.

#### **STAR\*METHODS**

#### **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins		
Non-clustered protocadherin proteins	This paper	N/A
Clustered protocadherin proteins	Rubinstein et al., 2015; Goodman et al., 2016a, 2016b; this paper	N/A
Polyethylenimine	Polysciences	Cat# 24765-2
Freestyle 293 Expression Media	Thermo Fisher Scientific	Cat# 12338-018
Opti-MEM Reduced Serum Media	Thermo Fisher Scientific	Cat# 31985-070
IMAC Sepharose 6 Fast Flow	GE Healthcare	Cat# 17092109
Biotin	Sigma	Cat# B4501
NeurAvidin-HRP	Thermo Fisher Scientific	Cat# 31030
Tris Base	Fisher Scientific	Cat# BP152-5
Sodium Chloride	Fisher Scientific	Cat# S271-10
Calcium Chloride Dihydrate	JT Baker	Cat# 1336-01
Imidazole	ACROS	Cat# 301870025
NeutrAvidin protein	Thermo Fisher Scientific	Cat# 31000
HEPES	Sigma	Cat# H3375
Tween-20	Sigma	Cat# P7949
BSA	Sigma	Cat# A7906
Series S CM4 chip	GE Healthcare	Cat# BR100539
Fetal Bovine Serum	Thermo Fisher Scientific	Cat# 16141079
DMEM with GlutaMAX	Thermo Fisher Scientific	Cat# 10569010
Penicillin Streptomycin	Thermo Fisher Scientific	Cat# 15070063
Glycerol	ACROS	Cat# 332031000
PEG 4,000	ACROS	Cat# 434630010
Bicine	Molecular Dimensions	Cat# MD2-003
Morpheus monosaccharides mix	Molecular Dimensions	Cat# MD2-100-75
PEG 8,000	Sigma	Cat# 89510
Ethylene Glycol	Fluka	Cat# 03760
Morpheus NPS mix	Molecular Dimensions	Cat# MD2-100-72
MES	Sigma	Cat# M3671
PEG 20,000	Sigma	Cat# 81300
PEG 550 monomethyl ether	Sigma	Cat# 202487
PEG 400	Sigma	Cat# 91893
Sodium Acetate	Sigma	Cat# S7545
Bicine	Sigma	Cat# B3876
Glutaraldehyde	Sigma	Cat# G5882
2R,3R)-(–)-2,3-Butanediol	Sigma	Cat# 237639
DOPC lipids	Avanti Polar Lipids	Cat# 850375C
DOGS-NTA lipids	Avanti Polar Lipids	Cat# 790404C
Rhodamine-DHPE lipids	Thermo Fisher Scientific	Cat# L1392
Potassium chloride	Sigma	Cat# P3911
300 mesh copper EM grids	Electron Microscopy Services	Cat# EMS300-Cu
Cellulose acetate	Sigma	Cat# 180955
Ethyl acetate	EMD	Cat# EX0241-6

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Critical Commercial Assays		
Spin Miniprep Kit	QIAGEN	Cat# 27106
Hispeed Plasmid Maxi Kit	QIAGEN	Cat# 12663
SF Cell Line 4D-Nucleofector® X Kit S	Lonza	Cat# V4XC-2032
Deposited Data		
Crystal structure of human pcdh1 EC1-4	This paper	PDB ID: 6VFP
Crystal structure of human pcdh10 EC1-4 monomer	This paper	PDB ID: 6VFQ
Crystal structure of human pcdh10 EC1-4 dimer	This paper	PDB ID: 6VFW
Crystal structure of human pcdh17 EC1-4	This paper	PDB ID: 6VFT
Crystal structure of human pcdh18 EC1-4	This paper	PDB ID: 6VFR
Crystal structure of human pcdh19 EC1-4	This paper	PDB ID: 6VFU
Crystal structure of human pcdh8 EC5-6	This paper	PDB ID: 6VFV
Crystal structure of Xenopus pcdh8.1 EC1-6	This paper	PDB ID: 6VG1
Crystal structure of human pcdh10 EC1-6	This paper	PDB ID: 6VG4
Human $\delta$ pcdh1 ectodomains on membranes, tomogram 1	This paper	EMDB: EMD-21188
Human $\delta$ pcdh1 ectodomains on membranes, tomogram 2	This paper	EMDB: EMD-21189
Human $\delta$ pcdh1 ectodomains on membranes, tomogram 3	This paper	EMDB: EMD-21190
Human $\delta$ pcdh10 ectodomains on membranes, tomogram 1	This paper	EMDB: EMD-21191
Human $\delta$ pcdh10 ectodomains on membranes, tomogram 2	This paper	EMDB: EMD-21192
Human $\delta$ pcdh10 ectodomains on membranes, tomogram 3	This paper	EMDB: EMD-21193
Experimental Models: Cell Lines	· ·	
Human: FreeStyle 293-F cells	Thermo Fisher Scientific	Cat# R79007
Human: K-562 bone marrow chronic myelogenous	ATCC	Cat# ATCC CCL-243
leukemia (CML) cells		
Recombinant DNA		
VRC-8400 vector	Vaccine Research Center (NIH), Gary Nabel	N/A
pmax-mCherry vector	T1 1 0011	N1/A
	Thu et al., 2014	N/A
BirA plasmid	Harrison et al., 2014	N/A N/A
BirA plasmid	Harrison et al., 2016	N/A
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA	Harrison et al., 2016 DNASU	N/A Cat# HsCD00399247
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA	Harrison et al., 2016 DNASU Transomic	N/A Cat# HsCD00399247 Cat# BC131967
BirA plasmid Human pcdh1 cDNA	Harrison et al., 2016 DNASU Transomic DNASU	N/A Cat# HsCD00399247 Cat# BC131967 Cat# HsCD00516491
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU	N/A Cat# HsCD00399247 Cat# BC131967 Cat# HsCD00516491 Cat# HsCD00083030
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA Human pcdh10 cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU	N/A Cat# HsCD00399247 Cat# BC131967 Cat# HsCD00516491 Cat# HsCD00083030 Cat# HsCD00045356
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA Human pcdh10 cDNA Human pcdh12 cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU	N/A         Cat# HsCD00399247         Cat# BC131967         Cat# HsCD00516491         Cat# HsCD0083030         Cat# HsCD00045356         Cat# HsCD00505992
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh17 cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU	N/A           Cat# HsCD00399247           Cat# BC131967           Cat# HsCD00516491           Cat# HsCD0083030           Cat# HsCD00045356           Cat# HsCD00505992           Cat# HsCD00641460
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA Human pcdh10 cDNA Human pcdh12 cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU DNASU DNASU	N/A           Cat# HsCD00399247           Cat# BC131967           Cat# HsCD00516491           Cat# HsCD00083030           Cat# HsCD00045356           Cat# HsCD00505992           Cat# HsCD00641460           N/A
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh17 cDNA Human pcdh18 cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU DNASU DNASU Dr. Chan Aye Thu Dr. Chan Aye Thu	N/A           Cat# HsCD00399247           Cat# BC131967           Cat# HsCD00516491           Cat# HsCD0083030           Cat# HsCD00045356           Cat# HsCD00505992           Cat# HsCD00641460           N/A
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh17 cDNA Human pcdh18 cDNA Human pcdh19 cDNA Human pcdh19 cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU DNASU DNASU Dr. Chan Aye Thu Dr. Chan Aye Thu	N/A         Cat# HsCD00399247         Cat# BC131967         Cat# HsCD00516491         Cat# HsCD0083030         Cat# HsCD00045356         Cat# HsCD000505992         Cat# HsCD00641460         N/A         N/A
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh17 cDNA Human pcdh18 cDNA Human pcdh19 cDNA Human pcdh19 cDNA Xenopus pcdh8.1 cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU DNASU Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu DNASU	N/A           Cat# HsCD00399247           Cat# BC131967           Cat# HsCD00516491           Cat# HsCD00083030           Cat# HsCD00045356           Cat# HsCD00505992           Cat# HsCD00641460           N/A           N/A           Cat# HsCD00399990
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh10 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh17 cDNA Human pcdh18 cDNA Human pcdh18 cDNA Human pcdh19 cDNA Kenopus pcdh8.1 cDNA Xenopus pcdh8.2 (PAPC) cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu DNASU Transomic	N/A           Cat# HsCD00399247           Cat# BC131967           Cat# HsCD00516491           Cat# HsCD0083030           Cat# HsCD0045356           Cat# HsCD00505992           Cat# HsCD00641460           N/A           N/A           N/A           Cat# HsCD00399990           Cat# HsCD00399990
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh17 cDNA Human pcdh18 cDNA Human pcdh19 cDNA Human pcdh19 cDNA Xenopus pcdh8.1 cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu DNASU Transomic	N/A           Cat# HsCD00399247           Cat# BC131967           Cat# HsCD00516491           Cat# HsCD0083030           Cat# HsCD0045356           Cat# HsCD00505992           Cat# HsCD00641460           N/A           N/A           N/A           Cat# HsCD00399990           Cat# HsCD00399990
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh10 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh12 cDNA Human pcdh18 cDNA Human pcdh18 cDNA Human pcdh18 cDNA Kanopus pcdh8.1 cDNA Xenopus pcdh8.2 (PAPC) cDNA Software and Algorithms XDS	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu DNASU Transomic DNASU	N/A         Cat# HsCD00399247         Cat# BC131967         Cat# HsCD00516491         Cat# HsCD0083030         Cat# HsCD00045356         Cat# HsCD00505992         Cat# HsCD00641460         N/A         N/A         N/A         Cat# HsCD00399990         Cat# BC074360         Cat# XLCD00716163
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh11Y cDNA Human pcdh8 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh12 cDNA Human pcdh18 cDNA Human pcdh18 cDNA Human pcdh19 cDNA Kenopus pcdh8.1 cDNA Xenopus pcdh8.2 (PAPC) cDNA Software and Algorithms XDS CCP4	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu DNASU Transomic DNASU Kabsch, 2010	N/A         Cat# HsCD00399247         Cat# BC131967         Cat# HsCD00516491         Cat# HsCD00045356         Cat# HsCD00045356         Cat# HsCD000641460         N/A         N/A         N/A         Cat# HsCD00399990         Cat# BC074360         Cat# XLCD00716163
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh1Y cDNA Human pcdh1Y cDNA Human pcdh10 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh17 cDNA Human pcdh18 cDNA Human pcdh18 cDNA Human pcdh19 cDNA Kenopus pcdh8.1 cDNA Xenopus pcdh8.2 (PAPC) cDNA	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu DNASU Transomic DNASU Kabsch, 2010 Winn et al., 2011	N/A         Cat# HsCD00399247         Cat# BC131967         Cat# HsCD00516491         Cat# HsCD0083030         Cat# HsCD00045356         Cat# HsCD00505992         Cat# HsCD00641460         N/A         N/A         N/A         Cat# HsCD00399990         Cat# BC074360         Cat# XLCD00716163
BirA plasmid Human pcdh1 cDNA Mouse pcdh7 cDNA Human pcdh9 cDNA Human pcdh10 cDNA Human pcdh10 cDNA Human pcdh10 cDNA Human pcdh12 cDNA Human pcdh12 cDNA Human pcdh18 cDNA Human pcdh18 cDNA Kenopus pcdh8.1 cDNA Xenopus pcdh8.1 cDNA Xenopus pcdh8.2 (PAPC) cDNA Software and Algorithms XDS CCP4 AIMLESS	Harrison et al., 2016 DNASU Transomic DNASU DNASU DNASU DNASU DNASU DNASU Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu Dr. Chan Aye Thu MASU Transomic DNASU Transomic DNASU Transomic DNASU	N/A         Cat# HsCD00399247         Cat# BC131967         Cat# HsCD00516491         Cat# HsCD0083030         Cat# HsCD00045356         Cat# HsCD000505992         Cat# HsCD00641460         N/A         N/A         N/A         Cat# HsCD00399990         Cat# HsCD00399990         Cat# BC074360         Cat# XLCD00716163

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Staraniso Server	Global Phasing	https://staraniso.globalphasing.org/cgi-bin/ staraniso.cgi
Pymol	Schrödinger	https://pymol.org/2/
PDBePISA	Krissinel and Henrick, 2007	http://www.ebi.ac.uk/pdbe/pisa/
TLSMD server	Painter and Merritt, 2006	http://skuld.bmsc.washington.edu/~tlsmd/
Scrubber 2.0	BioLogic Software	http://www.biologic.com.au
SednTerp	Dr. Thomas Laue	http://bitcwiki.sr.unh.edu/index.php/ Main_Page
HeteroAnalysis	Cole et al., 2008	https://core.uconn.edu/auf
Multalin	Corpet, 1988	http://multalin.toulouse.inra.fr/multalin/
ESPript	Robert and Gouet, 2014	http://espript.ibcp.fr
WebLogo 3.0	Crooks et al., 2004	http://weblogo.threeplusone.com/
Leginon	Suloway et al., 2005, 2009	https://emg.nysbc.org/redmine/ projects/leginon/wiki/Leginon_Homepage
MotionCor2	Zheng et al., 2017	https://emcore.ucsf.edu/ucsf- motioncor2
Appion-Protomo	Lander et al., 2009; Noble and Stagg, 2015; Winkler and Taylor, 2006	https://emg.nysbc.org/redmine/ projects/appion/wiki/Appion_Home; http://www.electrontomography.org/
Tomo3D SIRT	Agulleiro and Fernandez, 2015	https://sites.google.com/site/ 3demimageprocessing/tomo3d
3dmod	Kremer et al., 1996	https://bio3d.colorado.edu/imod/
Fiji	Schindelin et al., 2012	https://imagej.net/Fiji

#### LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Lawrence Shapiro (Iss8@columbia.edu). All unique/stable reagents generated in this study are available from the Lead Contact without restriction.

#### **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

The Freestyle 293F cell line was obtained from Thermo Fisher Scientific and is derived from the parental Human Embryonic Kidney (HEK) 293 cell line, of which the sex is female. Freestyle 293F cells were cultured in suspension in Freestyle 293 Expression medium at  $37^{\circ}$ C and 10% CO<sub>2</sub>. Human K-562 bone marrow chronic myelogenous leukemia (CML) cells, of which the sex is female, were obtained from ATCC and cultured in DMEM/10% FBS at  $37^{\circ}$ C and 5% CO<sub>2</sub>.

#### **METHOD DETAILS**

#### **Cloning and expression of recombinant proteins**

Complementary DNA (cDNA) clones encoding full-length human  $\delta$  protocadherins -17, -18 and -19 were a kind gift from Dr. Chan Aye Thu (Columbia University). Clones encoding human protocadherins -1, -8, -9, -10,  $-11_{Y}$ , -12, and -20, mouse pcdh7, and *Xenopus* pcdh8.1 and pcdh8.2 were obtained from the DNASU plasmid repository or Transomic Inc. Mouse pcdh8 was obtained from a cDNA library derived from day 15 embryo (Clontech). All constructs hereafter refer to human orthologs except where specified and amino acid numbering refers to the mature protein following signal peptide cleavage predicted using the SignalP server (Almagro Armenteros et al., 2019). Regions encoding full ectodomains of pcdh1 ( $_1$ -TRV-RGN-795), pcdh7 ( $_1$ -KQL-RLS-849, mouse), pcdh9 ( $_1$ -QEL-YLT-791), pcdh11<sub>Y</sub> ( $_1$ -QEK-YVK-789), pcdh20 ( $_1$ -SYS-MPT-829), pcdh8 ( $_1$ -KTV-VTA-683, human and  $_1$ -KTV-VTA-683, mouse), *Xenopus* pcdh8.1 ( $_1$ -KTV-LVT-641), *Xenopus* pcdh8.2 ( $_1$ -EIA-LTD-646), pcdh10 ( $_1$ -SQL-LVD-662), pcdh12 ( $_1$ -LTV-FVT-668), pcdh17 ( $_1$ -LKN-DMS-688), pcdh18 ( $_1$ -KNL-IFE-651), and pcdh19 ( $_1$ -LIN-NLS-657) or truncated ectodomain fragments pcdh1 EC1-3 ( $_1$ -TRV-VKD-322), pcdh1 EC1-4 ( $_1$ -CRU-VKD-441), pcdh1 EC5-7 ( $_{442}$ -VND- RGN-795), mouse pcdh7 EC1-4 ( $_1$ -KQL-VGD-497), pcdh9 EC1-4 ( $_1$ -QEL-LED-438), pcdh10 EC1-4 ( $_1$ -QEK-VKD-435), pcdh8 EC1-4 ( $_1$ -KTV-VD-662), pcdh17 EC1-4 ( $_1$ -LKN-ILD-447), pcdh18 EC1-4 ( $_1$ -LKN-ILD-447), pcdh18 EC1-4 ( $_1$ -KNL-IND-430), and pcdh19 EC1-4 ( $_1$ -LIN-ITD-424) were amplified by PCR from the respective full-length templates.

Ectodomain sequences of pcdhs -1, -7, -9, -11, -20, -17 and -19 and pcdh1 EC5-7 included up to 38 residues belonging to a 'stalk' region between the end of the last EC domain and the start of the start of the transmembrane region in the full-length protein whose inclusion was found to improve expression and solubility; these regions were not included for pcdh -8, -8.1, -8.2, -10, -12, -and -18, however, an additional pcdh10 construct containing this region, pcdh 10 EC1-6<sub>ECD</sub>( $_1$ -SQL-DLT<sub>-698</sub>) was prepared for use in liposome experiments. Amplicons were inserted between Not1/BamH1 sites of the mammalian expression vector VRC8400 (Barouch et al., 2005) preceded by the signal sequence of human Binding immunoglobulin protein (BiP; MKLSLVAAMLLLL-SAARA) and followed by a hexahistidine tag and stop codon. Human pcdh7 EC1-4 ( $_1$ -KQL-VGD- $_{497}$ ) fragment, for which cDNA was not available, was prepared from the mouse construct by mutagenesis using the Quikchange method (Invitrogen). *Trans* interface mutant constructs were prepared in the same way. Fidelity of all expression constructs was checked by DNA sequencing and was matched to amino acid sequences of Uniprot entries Uniprot: Q08174 (pcdh1), A0A0A6YY83 (mouse pcdh7), O60245 (human pcdh7), Q9HC56 (pcdh9), Q9BZA8 (pcdh11), O95206 (human pcdh8), Q7TSK3 (mouse pcdh8), Q6GLU2 (*Xenopus* pcdh8.1), A0A1L8HHP1 (*Xenopus* pcdh8.2), Q9P2E7 (pcdh10), Q9NPG4 (pcdh12), O14917 (pcdh17), Q9HCL0 (pcdh18), and Q8TAB3 (pcdh19).

For protein expression, Freestyle HEK293 cells (Thermo Fisher Scientific) grown in suspension were transiently transfected using Polyethyleneimmine (Baldi et al., 2012) diluted in Opti-Mem reduced serum medium (Thermo Fisher Scientific). Transfected cells were maintained in Freestyle cell culture medium (Thermo Fisher Scientific) supplemented with 5mM CaCl<sub>2</sub> 16 hours after transfection to improve cadherin yield. After six days, secreted hexahistidine-tagged cadherins were collected from conditioned media by nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography using a batch procedure (1h, 25°C) followed by further purification by size-exclusion chromatography using a Superdex 200 26/60 column (GE Healthcare) on an AKTA pure fast protein liquid chromatography system (GE Healthcare). Purified proteins were concentrated to between 2 and 22mg/mL in 150mM NaCl, 10mM Tris-Cl pH8.0, 3mM CaCl<sub>2</sub> and flash frozen in liquid nitrogen for long-term storage.

Constructs encoding biotinylated EC1-4 (pcdhs -1, -7, -8, -9, -10, -11, -17, -18, -19) or EC1-EC6 (pcdh12) fragments were prepared by insertion of an Avi-tag (GLNDIFEAQKIEWHE)-encoding sequence between the hexa-histidine-tag and stop codon. These were co-transfected with a plasmid encoding the biotin-Ligase BirA from *E. coli* (Lys2-Lys321) that included a BiP signal sequence and a C-terminal endoplasmic reticulum-retention signal (DYKDEL) prepared previously (Harrison et al.,2016) according to the method of Barat and Wu (2007). Expression plasmid and BirA plasmid were mixed at a 9:1 ratio for transfection and 50  $\mu$ M Biotin (Sigma) was added to the media after 16 hours. Purification was carried out exactly as for the non-biotinylated constructs and biotinylation was confirmed by western blot using NeutrAvidin-HRP (Pierce).

*Trans* binding fragments of clustered protocadherins  $\alpha$ 7 (EC1-5),  $\beta$ 6 (EC1-4),  $\gamma$ A8(EC1-4),  $\gamma$ B2(EC1-5) and  $\gamma$ C4(EC1-4) were prepared as described previously (Goodman et al., 2016a, 2016b; Rubinstein et al., 2015) using a similar method to that described for  $\delta$  protocadherins. Biotinylated forms were prepared as described above.

#### **SPR binding experiments**

SPR binding experiments were performed using a Biacore T100 biosensor equipped with a Series S CM4 sensor chip, immobilized with NeutrAvidin over all four flow cells. NeutrAvidin immobilization was performed in HBS-P buffer (0.01 M HEPES, 0.15 M NaCl, 0.05% v/v Tween-20, pH 7.4) at 32°C, over all four surfaces using amine-coupling chemistry as described in Katsamba et al. (2009), resulting in approximately 10,000 RU of NeutrAvidin immobilized. Binding experiments were performed at 25°C in a running buffer containing 10 mM Tris-Cl pH 7.4, 150 mM NaCl, 3mM CaCl<sub>2</sub>, 0.5 mg/mL BSA and 0.005% (v/v) Tween-20.

Biotinylated pcdh1, -7, -9, -11, -10, -12, -17, -18, -19 proteins comprising domains EC1-6 (pcdh12) or EC1-4 (all others) were captured over individual NeutrAvidin-immobilized surfaces at 1100-1300 RU using a flow rate of 20 µL/min. A NeutrAvidin-immobilized flow cell was used as a reference in each experiment to subtract bulk refractive index changes. Pcdh analytes and their respective mutants, as shown in Figures 1 and 4, were prepared in running buffer and tested for binding at 3, 9 and 27 µM, in order of increasing concentration, with each concentration series tested in duplicate to confirm reproducibility. In each binding cycle, a protein sample was injected over the captured surfaces at 50 µL/min for 60 s, followed by 120 s of dissociation phase, a running buffer wash step and a buffer injection at 100 µL/min for 60 s. After three binding cycles, buffer was used as an analyte instead of a protein sample to double reference the binding responses by removing systematic noise and instrument drift. The data was processed using Scrubber 2.0 (BioLogic Software). Binding responses were normalized for molecular weight differences between the ectodomains of each protein.

EC1-4 fragments of pcdhs -1, -7, -10 and -18 were also tested for binding at 3, 9 and 27  $\mu$ M over surfaces of biotinylated clustered pcdhs  $\alpha$ 7 (EC1-5),  $\beta$ 6 (EC1-4),  $\gamma$ A8(EC1-4),  $\gamma$ B2(EC1-5) and  $\gamma$ C4(EC1-4), captured at 1700-3000 RU. Experiments were performed at 25°C in a running buffer containing 10 mM Tris-Cl pH 8.0, 150 mM NaCl, 3mM CaCl<sub>2</sub>, 20 mM imidazole, 0.25 mg/mL BSA and 0.005% (v/v) Tween-20. Binding was tested using the same parameters as described above, except that a 40 s analyte contact time, followed by a 90 s dissociation phase was used. Clustered pcdhs  $\alpha$ 7 (EC1-5),  $\beta$ 6 (EC1-4),  $\gamma$ A8(EC1-4),  $\gamma$ B2(EC1-5) and  $\gamma$ C4(EC1-4) were tested for homophilic binding over their respective biotinylated surfaces at 0.1, 0.3, 0.89, 2.67, 8 and 24  $\mu$ M.

#### Analytical ultracentrifugation

Equilibrium analytical ultracentrifugation experiments were performed using a Beckman XLA/I ultracentrifuge, with a Ti50An or Ti60An rotor. Prior to each experiment, all proteins were diluted with buffer (150 mM NaCl, 10 mM Tris-Cl pH 7.4, 3 mM CaCl<sub>2</sub>)

and dialyzed for 16 hours at  $4^{\circ}$ C in the same buffer. 120 µL of proteins at three different concentrations (Abs 280nm at 10 mm of 0.65, 0.43 and 0.23, repectively), were loaded into six-channel equilibrium cells with parallel sides and sapphire windows. We performed all experiments at 25°C and collected UV data at 280 nm, using dialysis buffer as blank. Pcdh8 EC1-6 from mouse and human showed a tendency to non-specifically aggregate when samples thawed from  $-80^{\circ}$  storage were analyzed so unfrozen protein collected immediately following purification was used. EC1-6 and EC1-7 full ectodomain fragments were spun for 20 hours at 11000 rpm, increasing to 14000 rpm, 17000 rpm, and 20000 rpm for 10 hours each. Four scans (one per hour) were collected at each speed for the three concentrations to yield 48 scans per sample. Two, three and four ectodomain fragments were analyzed using the same protocol, except that 15000 rpm, 19000 rpm, 23000 rpm and 27000 rpm were used. We calculated the buffer density and protein v-bars using the program SednTerp (Alliance Protein Laboratories), and analyzed the retrieved data using HeteroAnalysis 1.1.44 (http://biotech.uconn.edu/auf; Cole et al., 2008). We fitted data from all concentrations and speeds globally by nonlinear regression to either a monomer-dimer equilibrium model or an ideal monomer model. All experiments were performed at least in duplicate.

#### Size-exclusion chromatography with multi-angle light scattering (SEC-MALS)

SEC-MALS analyses were performed using a Superdex 200 Increase 3.2/300 size exclusion column on an AKTA FPLC system (GE healthcare) coupled to inline static light scattering (Dawn Heleos II, Wyatt Technology), differential refractive index (Optilab rEX, Wyatt Technology) and UV detection. Purified ectodomains were diluted to 24  $\mu$ M in running buffer (150mM NaCl, 10mM Tris-Cl pH 7.4, 3mM CaCl<sub>2</sub>) and 50ul samples were run at a flow rate of 0.5ml/min at 25°C. Mixtures of membrane-proximal pcdh fragments were prepared in the same buffer at final concentrations of 100  $\mu$ M for each protein and incubated for 20 minutes at 25°C prior to running under the same conditions. All proteins eluted as single peaks, shown in Figure S1. Data were analyzed using ASTRA software (Wyatt Technologies).

#### K562 cell aggregation assays

Full-length human Pcdhs were cloned into the pmax-mCherry expression vector encoding a C-terminal mCherry-tag, then transfected into K562 cells (ATCC CCL243) as previously described (Goodman et al., 2017; Thu et al., 2014). Briefly, K562 cells were cultured at 37°C with 5% CO2 in DMEM with GlutaMAX (GIBCO) supplemented with 10% FBS and 1% penicillin-streptomycin. After two days, cells were counted, centrifuged, and resuspended in SF Cell Line 4D-Nucleofector Solution SF with supplement according to manufacturer's instructions (Lonza) at a density of ~1.5x104 cells/ $\mu$ L. For each experiment, 2  $\mu$ g of the Pcdh expression construct were transfected into 20  $\mu$ L of the K562 cell suspension by electroporation using an Amaxa 4D-Nucleofector (Lonza). Transfected cells were transferred to a 24-well plate in 500  $\mu$ L of medium per well and incubated overnight at 37°C and 5% CO2. Cells then were mixed by gentle rocking for 4 hours and imaged with an Olympus IX73 fluorescent microscope to determine the extent of aggregation.

#### Protein crystallization and structure determination

Crystals were grown using a hanging drop method in which 0.6-1.2 µL of purified protein were mixed with 0.6-1.2 µL of crystallization solution and incubated at 23°C for 1-10 days. Crystallization conditions for human pcdh1 EC1-4 (13.3mg/ml) were 8.5% (w/v) PEG 4000, 20% (v/v) glycerol, 0.1M tris-bicine buffer pH8.5, 0.1M Morpheus monosaccharides mix (0.02 M D-glucose, 0.02 M D-mannose, 0.02 M D-galactose, 0.02 M L-fucose, 0.02 M D-xylose, 0.02 M N-acetyl-D-glucosamine; Molecular Dimensions) with no further cryoprotection; those for Xenopus pcdh8.1 EC1-6 were 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.135M nitrate-phosphate-sulfate mix (0.045M sodium phosphate dibasic dihydrate, 0.045M Ammonium sulfate, 0.045 M sodium nitrate; Molecular Dimensions), 0.1M MES/imidazole buffer pH 6.5 with no further cryoprotection; those for human pcdh8 EC5-6 (13.5mg/ml) were 10% PEG 20 000 (w/v), 20% (v/v) PEG 550 monomethylether, 0.12M Morpheus ethylene glycols mix (0.03M diethyleneglycol, 0.03M triethyleneglycol, 0.03M tetraethyleneglycol, 0.03M pentaethyleneglycol; Molecular Dimensions), 0.1M MES/ imidazole buffer pH 6.5 with no further cryoprotection; those for human pcdh10 EC1-4 (10.8mg/ml) monomer form were 14% PEG 400 (v/v), 0.1M sodium acetate pH 4.6, 0.1M CaCl<sub>2</sub>, with 30% ethylene glycol (v/v) added as cryoprotectant; those for pcdh10 EC1-4 (21.5mg/ml) dimer form were 12% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.1M Tris-bicine buffer pH8.5, 0.1M Morpheus monosaccharides mix (0.02 M D-glucose, 0.02 M D-mannose, 0.02 M D-galactose, 0.02 M L-fucose, 0.02 M D-xylose, 0.02 M N-acetyl-D-glucosamine; Molecular Dimensions) with no further cryoprotection; those for human pcdh10 EC1-6 (15.1mg/ml) were 0.22M CaCl<sub>2</sub>, 0.1M Na Acetate pH 5.0 with 30% (v/v) glycerol as cryoprotectant and glutaraldehyde (0.5% v/v) added to the reservoir after crystal formation to aid crystal stability by cross-linking; conditions for human pcdh17 EC1-4 (8.8mg/ml) were 13%(w/v) PEG 4000, 0.3M NaCl, 0.1M MES pH 6.5, with 30% PEG 400 (v/v) added as cryoprotectant; those for human pcdh18 EC1-4 (12mg/ml) were 13% (w/v) PEG 20 000, 0.1M MES pH 6.5, with 30% (v/v) ethylene glycol added as cryoprotectant; and conditions for human pcdh19 EC1-4 (13.3mg/ml) were 7% (w/v) PEG 4000, 0.2M NaCl, 0.05M MES pH6.5, with 15% (v/v) butanediol (2R,3R) added as cryoprotectant.

Data were collected from single frozen crystals at 100K using a wavelength of 0.979Å at the Northeastern Collaborative Access Team beamlines 24-ID-E and –C at the Advanced Photon Source, Argonne National Laboratory, Argonne Illinois, USA. Data were processed and scaled using XDS (Kabsch, 2010) and merged using AIMLESS (Evans and Murshudov, 2013) as part of the ccp4-suite (Winn et al., 2011). Severe diffraction anisotropy was observed for pcdh10 EC1-6 and ellipsoidal truncation of the data was performed using the Staraniso server (http://staraniso.globalphasing.org/cgi-bin/staraniso.cgi) using the default I/sigl threshold of 1.2. Using

this limit, the region of included reflections was approximated by an ellipsoid extending to 4.2, 4.2 and 2.7Å for pcdh10 EC1-6 and 3.0/3.0/2.0Å for pcdh8.1 along the principal axes a\*, b\*, and c\*. While Staraniso indicated that data for pcdh10 EC1-6 extended to 2.7Å in the strongest direction, data were manually truncated at 3.3A (resolution limits 4.2/4.2/3.3 along a\*, b\*, c\*) since inclusion of the additional ~2000 reflections was not found to substantially improve model residuals or geometry in paired refinement tests. For both structures, the ellipsoidally truncated data were used for refinement since the treatment strongly improved the interpretability of  $F_o$ - $F_c$  maps. Unwanted 'filling' of the removed data by  $F_{calc}$  in map calculation was circumvented by removal of the respective indices in the mtz file using SFTOOLS in the ccp4 suite (Winn et al., 2011), as recommended in the Staraniso documentation. Data quality statistics are listed in Table S1.

Structures were solved by molecular replacement using Phaser (McCoy et al., 2007) as part of the phenix suite (Adams et al., 2010). Domains EC1-2 and EC4 of pcdh α4 EC1-4 (PDB: 5dzw), and EC3 of pcdh β1 EC1-3 (PDB: 4zpl) were used as search models for pcdh1 EC1-4. Domains EC1-4 of pcdh a7 EC1-5 (5dzv) were used as a search model for pcdh10 monomer form and the refined pcdh10 structure was then subsequently used as a search model for the pcdh10 dimer form and for the EC1-4 structures of pcdhs -17, -18, and -19. Pcdh8 EC5-6 was solved using the EC5 and EC6 domains from the structure of pcdh yB2 EC3-6 (PDB: 5szr); the refined structure of pcdh8 EC5-6 was then used in combination with the pcdh10 monomer structure to solve the full ectodomain structures of pcdh8.1 and pcdh10. Structures were refined by iterative rounds of model building in Coot (Emsley et al., 2010) or phenix autobuild (Terwilliger et al., 2008) and automated refinement using phenix.refine (Afonine et al., 2012). Local torsional restraints between non-crystallographic symmetry-related chains were used in the early stages of refinement for all structures containing multiple chains in the crystallographic asymmetric unit: pcdh10 EC1-4 dimer (five chains), pcdh17 EC1-4 (four chains), pcdh18 EC1-4 (two chains), and pcdh19 EC1-4 (three-chains). Additional restraints for pcdh10 EC1-4 dimer and pcdh10 EC1-6 structures were generated using the pcdh10 EC1-4 monomer structure refined to higher resolution as an external reference model during early stages (pcdh10 EC1-6) or throughout refinement (pcdh10 EC1-4). Secondary structure restraints were also applied in phenix.refine for all structures. For pcdh19 EC1-4, superposition of zebrafish pcdh19 EC1-4 (PDB: 5iu9) was used to guide manual adjustment of ambiguous regions in late stages of refinement. In the structure of Xenopus pcdh8.1 EC1-6, EC6 domains of both chains were poorly ordered so the EC6 domain from the structure of human pcdh8 EC5-6 was used to closely guide manual building. B factor models, chosen based on data resolution (available reflections per model atom) and by comparison of R<sub>free</sub> values for different protocols, comprised: individual isotropic B factors for pcdh1 EC1-4 (4.8 reflections per atom), pcdh10 EC1-4 monomer form (6.7 reflections per atom) and pcdh18 EC1-4 (5.4 reflections per atom); individual isotropic B factors with translation-libration-screw (TLS) refinement for pcdh10 EC1-6 (one TLS group, 3.8 reflections per atom) and Xenopus pcdh8.1 EC1-6 (nine TLS groups, 6 reflections per atom); and simpler TLS-only models for pcdh10 EC1-4 dimer form (8 TLS groups, 3 reflections per atom), pcdh17 EC1-4 (16 groups, 1.8 reflections per atom), pcdh19 EC1-4 (12 groups, 2.8 reflections per atom) and pcdh8 EC5-6 (2 groups, 2.9 reflections per atom). TLS groups comprised whole chains or one or more contiguous EC domains, with precise boundaries determined using the TLSMD server (Painter and Merritt, 2006). Refinement statistics are listed in Table S1. For pcdh10 EC1-6, the refinement statistics listed in Table S1 refer to agreement of the model with the ellipsoidally truncated data (20-4.4/4.4/3.3A); corresponding Rwork/Rfree values against spherically truncated data (20-3.3A) were 0.2853/0.3297.

Pymol 1.7.4.4 (DeLano, W.L. Pymol: An open-source molecular graphics tool. (2002)) was used for structure visualization, superposition of structures, and for preparation of images for publication. The PISA program (Krissinel and Henrick, 2007) was used to calculate interfacial buried surface areas.

#### Sequence analysis

Multiple sequence alignments were prepared using Multalin (Corpet, 1988) and annotated using ESPript (http://espript.ibcp.fr; Robert and Gouet, 2014). Phylograms were prepared using the phylogeny.fr server (Dereeper et al., 2008) based on the multiple sequence alignment of full-length sequences. Protein distances were estimated according to Whelan and Goldman (2001). Sequence Logo representations were generated using WebLogo 3.0 (Crooks et al., 2004) using a default y axis representing information content scaled to a maximum of 4 bits and without using correction for low sequence numbers. Sequences of mouse clustered protocadherins used for preparation of Logo plots corresponded to Uniprot entries: Uniprot: Q91XX8, Q91XX7, Q91XX6, Q91XX5, Q91XX4, Q91XX3, Q91XX2 (pcdh  $\gamma$ B1-2, 4-8); Uniprot: Q91Y08, Q91Y00, Q91XZ7, Q91XZ6, Q91XZ5, Q91XZ4, Q91XZ3, Q91XZ2, E9Q5G2, Q91VE5, Q91UZ8, Q91Y07, Q91Y06, Q6PB90, Q91Y04, Q91Y03, Q91YD8, Q91Y02, Q91Y01, Q91XZ9, Q91V48, Q91XZ8 (pcdh  $\beta$ 1-22); Uniprot: Q91XZ0, Q91XY6, Q91XY5, Q91XY4, Q91XY3, Q91XY2, Q91XY1, Q91XY0, Q91XX9, Q91XY9, Q91XY9, Q91XY8, Q91XY7 (pcdh  $\gamma$ A1-12).

#### Liposome aggregation assay and sample preparation for cryo-ET experiments

Liposomes were prepared using a hydration and extrusion method according to the manufacturers protocol (Avanti Lipids) with a final 8:2 molar ratio of 2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) and the nickel salt of 1,2-dioleoyl-*sn*-glycero-3-([*N*(5-amino-1-carboxypentyl) iminodiaceticacid]-succinyl) (DOGS-NTA). For fluorescent microscopy experiments, 1% Rhodamine B 1,2-Dihexa-decanoyl-sn-Glycero-3-Phosphoethanolamine (rhodamine-DHPE) lipids (Thermo Fisher) were incorporated into the liposomes in addition to the standard composition of DOPC and DOGS-NTA. For all samples, after evaporation of chloroform under nitrogen, combined lipids were hydrated with assay buffer (100mM Potassium Chloride, 25mM HEPES pH 7.4, 3mM Calcium Chloride, 10% (v/v) glycerol) and large aggregates dispersed by five cycles of flash freezing in liquid nitrogen followed by rapid thaw at

37°C. Resuspended liposomes were extruded using membranes with a pore size of 100nm and stored at 4°C under a layer of nitrogen until use.

Aggregation assays were performed in a total volume of  $20\mu$ L, with a final concentration of  $500\mu$ M liposomes and  $7\mu$ M C-terminal hexa-histidine tagged purified protocadherin ectodomains (pcdh1 EC1-7, pcdh1 EC1-7 L359D, pcdh10 EC1-6<sub>ECD</sub>, pcdh10 EC1-6 L362D, or mouse pcdh  $\gamma$ B6 EC1-6). For 'uncoated' controls protein volume was replaced by sizing buffer. After addition of purified ectodomains to liposomes, aggregation assays were incubated for 7 hours. For fluorescent imaging,  $5\mu$ L of each suspension were transferred to microscopy slides and imaged using a Nikon Eclipse 800 microscope using Qcapture at a magnification of 4x. For electron microscopy, the large aggregates were gently broken up by trituration with a 10  $\mu$ L pipette tip prior grid preparation for electron microscopy Sciences) and 0.025% (w/v) cellulose acetate (Sigma) dissolved in ethyl acetate (EMD Biosciences) and were incubated with 3 $\mu$ l of each suspension of aggregated liposomes for 10 s at 85% relative humidity, blotted for 2.5sec and flash frozen in liquid ethane using a semi-automated approach by utilizing a Gatan CP3 plunge freezer.

#### **Tilt-series data collection and processing**

All tilt-series were acquired using a Titan Krios (FEI/Thermo Fisher) at 300 keV outfitted with a direct electron detector Gatan K2 Summit direct electron detector, a post-column Gatan Bioquantum image filter (GIF; Gatan, Inc.) and a spherical aberration corrector (CEOS GmbH) calibrated to have negligible spherical aberration. In addition, most of the tilt-series were collected using a Volta phase plate (FEI/Thermo Fisher). Data was collected sequential with a tilt-range of either  $-60^{\circ}$  to  $60^{\circ}$  with 2.2° increments or  $-55^{\circ}$  to  $55^{\circ}$  in 2° increments for protocadherin1 and -10, respectively using the MSI-T2 application in Leginon (Suloway et al., 2005, 2009) with 100 ms frames for each tilt image at a nominal defocus range of 3.5 and 4 microns. Total cumulative dose per tilt-series collected was between 81 and 189 e<sup>-</sup>/Å<sup>2</sup> with dose rates of approximately 8 e<sup>-</sup>/pixel/sec. Incident dose for the 0° tilt image was between 1.5 and 2.8 e<sup>-</sup>/Å<sup>2</sup>, and increased for higher tilt angles according to the cosine of the tilt angle. Tilt-series were collected at pixel sizes of 1.84 Å and 2.8 Å. Full-frame alignment was performed using MotionCor2 (Zheng et al., 2017) without dose weighting.

All tilt-series were aligned using Appion-Protomo (Lander et al., 2009; Noble and Stagg, 2015; Winkler and Taylor, 2006). After coarse alignment, tilt-series were manually aligned and then refined using a set of alignment thicknesses between 600 and 2,000Å. Refinement and manual alignment were iterated until refinements converged. The best aligned iteration was reconstructed for visual analysis using Tomo3D SIRT (Agulleiro and Fernandez, 2011, 2015) after moderate dose-compensation using the relation described in Grant and Grigorieff (2015). CTF correction was not performed. 3dmod (Kremer et al., 1996) was used to prepare the tomogram slices for Figure 6 and Videos S1, S2, S3, S4, and S5.

#### Intermembrane distance measurements

Intensity plot profiles were plotted using the analyze plot profile function in Fiji (Schindelin et al., 2012) for representative reconstituted junctions on tomogram slices. Measurements of 16 junctions each for pcdh 1 and pcdh 10 were taken from slices from the tomograms shown in Figure 6 and averaged. Reconstituted junctions were identified as described in the main text.

#### **QUANTIFICATION AND STATISTICAL ANALYSIS**

Statistics of X-ray diffraction datasets and crystal structures are reported in Table S1 and were determined using AIMLESS (Evans and Murshudov, 2013) and Phenix (Adams et al., 2010).

#### DATA AND CODE AVAILABILITY

The accession numbers for the crystal structure coordinates and structure factors of human pcdh1 EC1-4, pcdh10 EC1-4 monomer, pcdh10 EC1-4 dimer, pcdh17 EC1-4, pcdh18 EC1-4, pcdh19 EC1-4, pcdh8 EC5-6, pcdh10 EC1-6, and *Xenopus* pcdh 8.1 EC1-6 reported in this paper are PDB: 6VFP, 6VFQ, 6VFW, 6VFT, 6VFR, 6VFU, 6VFV, 6VG4, and 6VG1, respectively. The accession codes for tomograms 1-3 of pcdh1-coated liposomes and tomograms 1-3 of pcdh10-coated liposomes reported in this paper are EMDB: 21188, 21189, 21190, 21191, 21192, 21193.

Cell Reports, Volume 30

# **Supplemental Information**

## Family-wide Structural and Biophysical

## **Analysis of Binding Interactions**

## among Non-clustered $\delta$ -Protocadherins

Oliver J. Harrison, Julia Brasch, Phinikoula S. Katsamba, Goran Ahlsen, Alex J. Noble, Hanbin Dan, Rosemary V. Sampogna, Clinton S. Potter, Bridget Carragher, Barry Honig, and Lawrence Shapiro





Figure S1: SPR analysis of interactions between  $\delta$  and clustered protocadherin *trans-binding* fragments and domain-dependence of homophilic  $\delta$  pcdh homophilic binding, Related to Figure 1.

(A) Assessment of heterophilic binding of EC1-4 fragments of  $\delta$  pcdhs-1, -7, -10 and -18 to surfaces tethered with clustered pcdh fragments  $\alpha$ 7 EC1-5,  $\beta$ 6 EC1-4,  $\gamma$ A8 EC1-4,  $\gamma$ B2 EC1-5 and  $\gamma$ C4 EC1-4. Each  $\delta$  protocadherin was tested at three analyte concentrations (27, 9, and 3 $\mu$ M). (B) Homophilic binding of the respective clustered pcdhs  $\alpha$ 7 EC1-5,  $\beta$ 6 EC1-4,  $\gamma$ A8 EC1-4,  $\gamma$ B2 EC1-5 and  $\gamma$ C4 over surfaces tethered with biotinylated forms of the same proteins. Each clustered pcdh was tested at six concentrations, 24, 8, 2.67, .89, 0.3 and 0.1  $\mu$ M. (C) Binding of full ectodomains, deletion fragments, and point mutants of pcdh1 ( $\delta$ 1) and pcdh10 ( $\delta$ 2) over the respective full ectodomain surfaces. Analyte concentrations as in panel A.


### Figure S2



#### Figure S2: Analysis of δ protocadherin oligomerization state by SEC-MALS and cell aggregation, Related to Table 1.


Purified extracellular regions of  $\delta$  protocadherins analyzed using size exclusion chromatography (SEC) with in-line multi-angle light scattering (MALS). (A) Plots showing protein peaks as refractive index changes (RI, relative scale) against elution volume (ml). Each protocadherin migrated as a single peak. Apparent molecular masses calculated from light scattering analysis are plotted in blue at the peak positions; monomeric molecular masses determined by mass-spectrometry are indicated by a dotted line. All samples were loaded at 24µM concentration. Void volume of the SEC column is ~8ml. (B) SEC-MALS analyses of pairwise 1:1 mixtures of membrane-proximal domain fragments of pcdhs-1, -8 and -10 to test potential heterophilic interactions. Loading concentration 100µM for each protein. (C) Aggregation of K562 cells transiently transfected with full-length human pcdh-mCherry constructs or mCherry alone, visualized by fluorescence microscopy.

# Figure S3




#### Figure S3: Variations in overall *trans* dimer structure between $\delta$ protocadherin subtypes, Related to Figures 2 and 3.

(A) *Trans* dimer topologies of pcdhs-1, -10, -17, -18 and -19 (left to right) depicted as ribbons with molecular surfaces. Residues with at least 5% of their accessible surface area buried in the dimer are highlighted in magenta. Dashed boxes delimit EC1:4 and EC2:3 interface regions expanded in Figure 3. Arrow indicates regions of lesser contact in pcdh1. Half of each 2-fold symmetric dimer is shown. (B) Ca traces of *trans* dimers superposed over one protomer (background, gray traces) to show differences in orientation of the partner protomer (colored according to legend). (C) Individual protomers of the same set of structures as panel (B), superposed over domain EC2 to show differences in interdomain angles. (D) Molecular surfaces of single protomers (gray) with *trans* dimer interface residues highlighted in cyan (<5% buried) and blue (>5% buried). (E) RMSD values between Ca atoms of superposed whole *trans* dimer structures. Number of aligned Ca atoms indicated in parentheses.





**Figure S4: Divergent pcdh17 dimer and variations in interface loop conformations, Related to Figures 2 and 3.** (A) Ribbon view of two putative *trans* dimers of pcdh17 EC1-4 in the crystallographic asymmetric unit. Asterisk indicates a close non-*trans* dimer lattice contact between EC4 domains. Spheres: calcium ions. (B) Residue-level view of pcdh17 *trans* dimer interface regions EC1:EC4 (top) and EC2:EC3 (bottom). Side chains of interfacial residues (>5% buried) are shown as sticks; those conserved among  $\delta$ 2 pcdhs are highlighted gold. Leu359 (magenta, equivalent to Leu359 in pcdh10) is solvent exposed. Spheres: calcium ions. (C) Carbon  $\alpha$  traces of superposed EC domains from *trans* dimer structures of pcdhs -1, -10, -17, -18, and -19. Partner protomer in a representative dimer structure (pcdh10) is shown as a molecular surface (green). (D) Superpositions of domains EC2 (left panel) or EC3 (right panel) of monomer and dimer crystal forms of pcdh10, depicted as in panel C. Dashed lines indicate representative shifts.

# Figure S5




			А	В	-//- D-E loop	E -//-	G linker
			124	33			<b>214</b> 215
	Pcdh1	104-INDNTPNFASP	VITLAIPENT	NIGSLFPIP-LAS	165-A E D Q E - E K	QPQLI 209-	-LRVTV <b>LD</b>
	Pcdh7	106-INDNTPTFPSP	VLTLTVEENF	RPVGTLYLLP-TAT	219-A D T P D G E K	QPQLI 264	-LRVLI <b>T D</b>
	Pcdh9	112-T N D N A P M F P S P	VINISIPENI	LINSRF <b>P</b> IP-SAT	170-V E T P E G E K	W P Q L I 215	-LQVTV <mark>SD</mark>
	Pcdh11	109-INDNAPLFPAT	VINISIPENS	SAINSKY <mark>T</mark> LP-AAV	167-IETPEGDK	MPQLI 212-	-LQVSV <b>TD</b>
EC2	Pcdh20	142-INDNAPQFPVS	QISVWVPENA	A P V N T R L A I E H P A V	201-EENENGER	TPYLI 246	-LTIGI <mark>SD</mark>
202			115	123 124 125 128	157 161	<b>163</b> 165	225
	Pcdh10	98-INDNPPSFPEP	DLTVEISESA	TPG <b>TR</b> FPL <mark>E-S</mark> AF	155-Q T <mark>Q</mark> G D G N R	FAELV 219-	LTIRVL D
	Pcdh8	99-VNDHAPRFPRA	QIPVEVSEGA	AVG <b>TR</b> IPL <mark>E-V</mark> PV	159-Q T R A D G A Q	CADLV 202-	-LSVRVLD
	Pcdh12	99-INDHQPRFPKG	EQELEISESA	SLR <mark>TRIPLD-R</mark> AL	156-IV <u>G</u> PDE <b>T</b> K	HAELI 201-	-VKVNVL D
	Pcdh17	108-INDNAPSFSSD	QIEMDISENA	APGTRFPLT-SAH	167-KSRGDGTK	FPELV 212-	-INVKVID
	Pcdh18	103-INDNSPQFSRS	LIPIEISESA	AVG <b>TR</b> IPL <b>D-S</b> AF	160-R T R T D G A K	YAELI 205-	-LKISIS D
	Pcdh19	101-LNDNAPSFPAA	QIELEI <mark>S</mark> EAA	A S P G T R I P L D - S A Y	<sup>158</sup> -K T <mark>R</mark> G D G <mark>S</mark> R	FAELV 203-	-LSIKVT <mark>D</mark>





#### Figure S5: Multiple sequence alignment of human δ protocadherin adhesive domains EC1-4, Related to Figure 3.

Aligned amino acid sequences are separated into  $\delta 1$  and  $\delta 2$  subfamilies (top and bottom); secondary structure derives from the pcdh1 structure. Interfacial residue positions from *trans* dimer structures of pcdh1 ( $\delta 1$ ) or pcdh10 ( $\delta 2$ ) are shaded in all sequences according to amino acid type (gray:nonpolar/aromatic, green:polar, blue:basic, red:acidic, unshaded:glycine) and numbered in gold (conserved in character within subfamily) or purple (non-conserved). Interface numbering refers to pcdh1(top) and pcdh10 (bottom). Interface residues that coordinate Calcium are numbered in green. Pcdh8, which may dimerize weakly, was excluded from  $\delta 2$  conservation determination. Omitted non-interface regions are indicated by "..." in alignment and by "-//-" in secondary structure.



#### Figure S6: Sequence Logo plot of aligned putative cis dimerization regions, Related to Figure 5.

Amino acid sequences of EC5-6 regions of mouse  $\beta$ ,  $\gamma A$ , and  $\gamma B$  clustered protocadherins; EC5-6 regions of human  $\delta 2$  protocadherins; and EC6-7 regions of human  $\delta 1$  protocadherins were each aligned to produce Logo plots showing conservation at each residue position. Residue numbering on x axis is based on mouse pcdh  $\gamma B7$  (top plots), human pcdh10 (middle plots), and human pcdh1 (bottom plots); y axis shows estimated information content in bits. Alignments for each domain are displayed separately. Residues whose side chains are buried (>20% ASA) in the *cis* dimer interface of  $\gamma B7$  (PDB:5v5x) and the equivalent positions in  $\delta$  protocadherins are highlighted with arrows and yellow shading. Calcium co-ordinating residues, which are highly conserved, are marked with green circles above the plots.

	Pedh1 EC1-4	Pedh10 EC1-4	Pedh10 EC1-4	Pedh17 EC1-4	Pedh18 EC1-4	Pcdh19 EC1-4	Pedh8 EC5-6	Pedh8.1 EC1-6		Pedh10 EC1-6	1-6		
	human	<i>Monomer form</i> human	<i>Dumer Jorm</i> human	human	human	human	human	Xenopus		human			
DATA COLLECTION													
Space group	P6122	P2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	3	3	C2	P3 <sub>2</sub> 21	$P2_1$	P2 <sub>1</sub>		P41212			
Cell dimensions: $a, b, c$ (Å)	148.6, 148.6, 149.9	26.4, 78.9, 238.9	346.6, 73.2, 246.33	214.6, 105.8, 101.4	127.0, 177.0, 71.9	109.0, 109.0, 309.7	41.7, 29.5, 92.4	146.7, 42.4, 167.5		84.1, 84.1, 543.9	43.9		
α, β, γ (°)	90, 90, 120	90, 90, 90	90, 132.1, 90	90, 101.0, 90	90, 101.4, 90	90, 90, 120	90, 98.5, 90	90, 110.6, 90		90, 90, 90			
								Spherical <sup>2</sup>	Ellipsoidal	Spherical <sup>2</sup>	af	Ellipsoidal	
Resolution (Å)	40-3.2 (3.42-3.20) <sup>1</sup>	40-2.3 (2.38-2.30)	40-3.6 (3.71-3.60)	40-3.7 (4.0-3.7)	40-2.8 (2.92-2.80)	40-3.5 (3.71-3.5)	40-2.9 (3.07-2.9)	40-2.0 (2.03-2.00)	40-3/3/2 (2.14-2.00)	40-5		40-4.2/4.2/3.3 (3.45-3.30)	-3.30)
R <sub>merge</sub>	0.12 (1.685)	0.10 (0.89)	0.123 (4.649)	0.211 (0.735)	0.083 (1.24)	0.14 (2.5)	0.13	0.13 (5.28)	0.77 (0.56)	0.139	(2.475) 0.093		0.52)
R <sub>meas</sub>		0.11 (1.00)	0.146 (5.476)	0.248 (0.866)	0.094 (1.41)	0.15 (2.6)	0.16	0.153 (6.03)	0.87 (0.62)	0.145	(2.570) 0.097		(0.54)
R <sub>pim</sub>	0.028 (0.394)	0.044 (0.44)	0.077 (2.871)	0.128 (0.451)	0.042 (0.64)	0.047 (0.814)	0.08	0.071 (2.87)	0.04 (0.27)	0.040	(0.687) 0.028		(0.15)
CC1/2	1.0 (0.81)	1.0 (0.83)	1.0 (0.29)	1.0 (0.71)		1.0 (0.72)	(17.0) 0.99	1.00 (0.37)	1.00 (0.88)	_	(0.95) 1.00		(0.98)
I/GI	15.9 (2.1)	11.0 (1.6)	5.4 (0.4)	5.4 (1.6)	10.2	9.4 (1.1)	8.2 (1.7)	5.8 (0.3)	12.5 (3.0)	10.7	(1.6) 16.5		(5.8)
Unique reflections	16 684 (2 938)	23 366 (2 283)	52 814 (4 543)	22 957 (4 468)	38 201 (4 506)	27 770 (4 378)	5 168 (803)	128 295 (6 132)	59 482 (2 974)	30 910	(4 386) 20 058	Ŭ	(1003)
Multiplicity	18.3 (19.1)	6.1 (4.7)	3.4 (3.6)	3.5 (3.4) 4.8	4.8 (4.6)	9.8 (10.4)	3.3 (2.3)	4.4 (4.1)	4.5 (4.9)	-	(13.7) 12.4		(11.9)
Completeness (%)	100.0 (100.0)	(8.8) 7.66	98.2 (98.3)	96.7 (92.1)	97.2 (91.4)	(6.66) (6.69)	(1.66) 0.99.6	97.5 (95.1)	45.1 (12.3)	7.66	(99.5) 64.7		(26.0)
Ellipsoid completeness (%)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	89.4 (88.8)	n/a	92.1		(97.3)
REFINEMENT													
Resolution (Å)	20-3.2	20-2.3	20-3.6	20-3.7	20-2.8	20-3.5	20-2.9		$20-3.0/3.0/2.0^3$		20	20-4.2/4.2/3.3 <sup>3</sup>	
Unique reflections	16 561	23 218	50 085	23 284	37912	27510	5 138		59 447		12771	71	
Molecules per a.s.u.	-	-	5	4	2	3	_		2		-		
R <sub>work</sub> Rfree	0.2255/0.2659	0.1943/0.2333	0.2737/0.2899	0.2508/0.2948	0.2480/0.2692	0.2581/0.2874	0.2250/0.2571		0.253/0.297		0.24	0.2410/0.2899	
No. atoms													
Protein	3 365	3 282	16 399	12 832	6 742	9 763	1 670		9 847		5006	9	
Ligand/ion	63	57	510	499	262	172	75		184		137		
Water	15	105	23	6	50	11	5		138		17		
B-factors													
Protein	134.22	57.7	233.3	119.6	110.5	174.0	47.8		69.0		94.3		
Ligand/ion	181.13	64.6	245.0	152.9	142.0	229.8	62.3		73.2		117.5	.5	
Water	104.53	50.51	225.1	89.3	98.9	130.0	42.0		37.8		36.9		
R.m.s deviations													
Bond lengths (Å)	0.0086	0.0130	0.0131	0.0079	0.0160	0.0046	0.0064		0.0057		0.0102	02	
Bond angles (°)	0.552	0.866	0.789	0.818	0.767	0.798	0.811		0.814		0.617	17	
Ramachandran													
Favored (%)	96.8	96.2	96.7	93.5	94.6	94.8	97.3		95.9		95.3		
Allowed (%)	3.2	3.8	3.3	6.5	5.4	5.2	2.7		4.1		4.7		
Outliers (%)	0	0	0	0	0	0	0		0		0		
PDR Accession	6VFD	6VEO	6VFW	AVET	6VFR	6VEI1	6VFV		1976		6VG4	2	
FDD Accession	DALT	2110	0 V F **	OVET	OVEN	UVFU	UVEV		1040			ţ	

Table S1: Crystallographic data collection and refinement statistics, Related to Figures 2 and 5

-i ci m

Values in parentheses refer to the highest resolution shell Data for pcdh8.1 and pcdh 10 EC1-6 were processed using truncation (Staraniso server) to exclude weak reflections due to diffraction anisotropy; additional values for spherical processing are shown Ellipsoidally truncated data were used in refinement

Table S1

## Table S2: Dimer buried surface areas (BSA), Related to Figure 2

	BSA dimer (Ų)	Hydrophobic BSA	BSA <sub>EC1:4</sub>	BSA <sub>EC2:3</sub>	BSA <sub>EC1 FG</sub> loop:EC2
Pcdh-1	2986	1859 (62%) <sup>2</sup>	2238 (75%)	652 (22%)	96 (3%)
Pcdh-10	3458 (A:C) <sup>1</sup>	2334 (68%)	1325 (38%)	2133 (62%)	0 (0%)
	3297 (B:D)	2236 (68%)	1137 (34%)	2161 (66%)	0 (0%)
	3529 (E:E)	2307 (65%)	1479 (42%)	2050 (58%)	0 (0%)
Pcdh-17	2024 (A:D)	1227 (61%)	932 (46%)	1011 (50%)	81 (4%)
	2071 (B:C)	1288 (62%)	937 (45%)	979 (47%)	155 (8%)
Pcdh-18	3719	2518 (69%)	2136 (57%)	1534 (42%)	49 (1%)
Pcdh-19	4176 (A:C)	3071 (74%)	1994 (48%)	2120 (51%)	62 (1%)
	4169 (B:B)	2933 (70%)	1918 (46%)	2252 (54%)	0 (0%)

Values for dimers in crystallographic asymmetric unit are listed separately, indicated by chain IDs
 Percentage of total dimer BSA

Tomogram	Tilt range	Nominal Defocus [µm]	Pixel size [Å]	EMDB	Description of biological content	
Pcdh1 #1	-39.9-42.9°	-4.02	2.7975	21188	δ1 Pcdh1 EC1-7 ectodomains accumulate at flattened junctional regions between	
Pcdh1 #2	-30.8-52.8°	-4.00	1.83586	21189	aggregated liposomes. Note apparent midlines and irregular distribution in top	
Pcdh1 #3	-46.2-44.0°	-4.00	1.83586	21190	views (between vertically stacked liposomes).	
Pcdh10 #1	-46.0-54.0°	-3.54	1.83586	21191	δ2 Pcdh10 EC1-6 ectodomains accumula	
Pcdh10 #2	-46.0-58.0°	-3.45	1.83586	21192	at flattened junctional regions between aggregated liposomes. Note irregular distribution in top views and apparent	
Pcdh10 #3	-52.0-50.0°	-3.44	1.83586	21193	disorder in junction side views	

## Table S3: Tomography data collection and deposition information, Related to Figure 6.